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STRUCTURAL, KINETIC AND MUTATIONAL ANALYSIS OF TWO
BACTERIAL CARBOXYLESTERASES
by
Ping Liu
Under the Direction of Irene T. Weber
ABSTRACT

The crystal structures of two thermostable carboxylesterase Est30 and Est55 from
Geobacillus stearothermophilus were determined to help understand their functions and
applications in industry or medicine. The crystal structure of Est30 was determined at
1.63 Å resolution by the multiple anomalous dispersion method. The two-domain Est30
structure showed a large domain with a modified alpha/beta hydrolase core including a
seven, rather than an eight-stranded beta sheet, and a smaller cap domain comprising
three alpha helices. A 100 Da tetrahedral ligand, propyl acetate, was observed to be
covalently bound to the side chain of Ser94 in the catalytic triad. This ligand complex
represents the first tetrahedral intermediate in the reaction mechanism. Therefore, this
Est30 crystal structure will help understand the mode of action of all enzymes in the
serine hydrolase superfamily.
Est55 is a bacterial homologue of the mammalian carboxylesterases involved in
hydrolysis and detoxification of numerous peptides and drugs and in prodrug activation.
Est55 crystals were grown at pH 6.2 and pH 6.8 and the structures were determined at
resolutions of 2.0 and 1.58 Å, respectively. Est55 folds into three domains, a catalytic

domain, an α/β domain and a regulatory domain. This structure is in an inactive form; the
side chain of His409, one of the catalytic triad residues, is pointing away from the active
site. Moreover, the adjacent Cys408 is triply oxidized and lies in the oxyanion hole,
which would block the entry of substrate to its binding site. This structure suggested a
self-inactivation mechanism, however, Cys408 is not essential for enzyme activity.
Mutation of Cys408 showed that hydrophobic side chains at this position were favorable,
while polar serine was unfavorable for enzyme activity.
Both Est30 and Est55 were shown to hydrolyze the prodrug CPT-11 into the
active form SN-38. Therefore, Est30 and Est55 are potential candidates for use with
irinotecan in cancer therapy. The catalytic efficiency (kcat/Km) of Est30 is about 10-fold
lower than that of Est55. The effects of the Cys408 substitutions on Est55 activity
differed for the two substrates, p-NP butyrate and CPT-11. Mutant C408V may provide a
more stable form of Est55.

INDEX WORDS: thermostable carboxylesterase, Geobacillus stearothermophilus,
crystal structure, multiple anomalous dispersion, alpha/beta hydrolase, tetrahedral
intermediate, reaction mechanism, prodrug activation, CPT-11, cancer gene therapy
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CHAPTER 1
General Introduction
Carboxylesterases and their classifications
Carboxylesterases (carboxylic ester hydrolase, EC 3.1.1.1) are a group of
enzymes that hydrolyze carboxylic ester bonds with relatively broad substrate specificity.
They are members of the α/β hydrolase family and can hydrolyze short chain aliphatic
and aromatic esters (Krish 1971). Both mammalian carboxylesterases and bacterial
carboxylesterases have enormous interest because of their important physiological,
industrial and medical roles in the synthesis and hydrolysis of stereospecific compounds
including the metabolic processing of drugs, and antimicrobial agents (Krish 1971;
Takayama 1998; Bornscheuer 2002).
Several carboxylesterases from bacterial origins have been identified and studied
(Morana 2002; Mnisi 2005). Generally, for bacterial carboxylesterases, attention has been
focused on their biotechnological potential because of their special characteristics such as
high regioselectivity, enantioselectivity and thermostability. Their potential in medicine
is rarely explored.
Enzymes can be classified based on either their substrate specificity or their
sequence similarity. The substrate specificity of carboxylesterases is very wide (Walker
1983). It has been shown that carboxylesterases have broad and overlapping substrate
specificity towards amides and esters and a single esterolytic reaction is mediated by
several enzymes. Therefore, it is impossible to classify carboxylesterases based on their
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substrate specificity. Arpigny (Arpigny 1999) and Satoh (Satoh 1998) have classified
microbial and mammalian carboxylesterases based on sequence similarities.
Microbial lipolytic enzymes including carboxylesterases and true lipases are
classified into eight families. Members of Family I are true lipases. The enzymes in
Family II (GDSL family) have a Gly-Asp-Ser-(Leu) (GDSL) motif instead of the
conventional pentapeptide Gly-Xaa-Ser-Xaa-Gly. Few enzymes have been identified in
Family III and the majority of them are lipases. Their structures display a canonical fold.
Family IV is called the hormone sensitive lipase (HSL) family because enzymes in this
family have a striking amino acid sequence similarity to the mammalian HSL. Enzymes
grouped in Family IV originate from mesophilic bacteria (Pseudomonas oleovorans,
Haemophilus influenzae, Acetobactr pasteurianus) as well as from cold-adapted
(Moraxella sp) or thermostable (Sulfolobus acidocaldarius) organisms. The unique
feature of enzymes in Family VI is their low molecular weight (23-26 KDa). They are the
smallest esterases known. Esterases from Family VII are rather large (~55 KDa) and
share significant homology to eukaryotic acetylcholine esterases and intestine or liver
carboxylesterases. A p-nitrobenzyl esterase from Bacillus subtilis and an esterase from
Arthrobacter oxydams belong to this group (Pohlenz 1992; Moore 1996; Arpigny 1999).
Interestingly, Family VIII enzymes show a significant similarity to several class C βlactamases. A region of 150 residues (from position 50 to 200) is 45% similar to an
Enterobacter cloacae ampC gene product (Arpigny 1999).
Mammalian carboxylesterases (EC 3.1.1.1) are from multiple gene families. The
gene products are located in the endoplasmic reticulum of many tissues (Hosokawa 1987;
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Hosokawa 1990; Yamada 1994; Hosokawa 1995; Satoh 1998; Mori 1999; Hosokawa
2001).

Satoh and Hosokawa proposed a novel classification and nomenclature of

carboxylesterase isozymes (Satoh 1998). Based on the sequence identity and the enzyme
characteristics, they proposed that carboxylesterase isozymes be classified into four
families, CES1, CES2, CES3, and CES4. According to the classification, human liver
carboxylesterase and rabbit liver carboxylesterase (rCE) belong to the CES1 family.

Carboxylesterase reaction mechanism
Carboxylesterase can perform ester hydrolysis and substrate transesterfication
reactions. The cleavage of the esters by carboxylesterases is base-mediated and requires
water as co-reactant. The reaction is achieved by the catalytic triad of Ser, Glu and His.
Site-directed mutagenesis of the catalytic Ser, His and Glu to Ala significantly reduced
the carboxylesterase activity, thus confirming the role of Glu and His in forming a
putative charge relay system with Ser (Taylor 1994). Frey (Frey 1994) demonstrated the
importance of low-barrier hydrogen bonds in the serine esterase reacion. The low-barrier
hydrogen bonds formed between His and Glu facilitate the action of nucleophilic attack
by the β-OH group of Ser on the acyl carbonyl group of chymotrypsin (Frey 1994). The
charged glutamic acid facilitates removal of a proton from histidine, resulting in the
transfer of proton from the adjacent serine to the opposing nitrogen of histidine. The
generated oxygen nucleophile subsequently attacks the carbonyl group of substrate. The
transition state is stabilized by low-barrier hydrogen bonds, which include the hydrogen
bond between His and Glu and the hydrogen bond between the tetrahedral oxyanion and
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the amides of two Gly. Then, the acyl-enzyme complex forms after removing a proton
from His and the alcohol is released. The deacylation reaction is the reverse of the
acylation step, which starts from a nucleophilic attack by a water molecule in identical
fashion to form the second tetrahedral intermediate, leading to the release of the
carboxylic acid and return of the enzyme in the original state (Satoh 1998).

Carboxylesterase structures
Although several carboxylesterase families have been identified, the molecular
structures are known for only a few carboxylesterases. Crystal structures are available for
two members of the hormone-sensitive lipase (HSL) family (Family IV), (De Simone
2000; De Simone 2001), one carboxylesterase from the Family VI (Kim 1997) and pNB
esterase from Family VII (Figure 1.1). These structures have a typical α/β hydrolase fold
(Ollis 1992; Heikinheimo 1999; Nardini 1999), with a central eight-stranded β sheet,
flanked by helices and connecting loops (Figure 1.2). The catalytic center contains a triad
of amino acid residues (Ser-His-Asp/Glu), responsible for the nucleophilic attack on the
carbonyl carbon atom of the ester bond. The nucleophile is located at the apex of a sharp
turn between a β strand and an α helix that is known as the nucleophile elbow.
Only two mammalian carboxylesterase structures have been determined (Figure
1.3). The first crystal structure of a mammalian carboxylesterase was that of rCE
(Bencharit 2002). rCE has the serine hydrolase fold observed in other esterases. Human
carboxylesterase 1 (hCE1) and rCE share 81% sequence identity and have a 0.68 Å root
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1JJI

1QE3

1MM3

2C7B

1EVQ

1AUO

Figure 1.1 Bacterial carboxylesterase structures. The four-letter code under each
structure is its code in the protein data bank.
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Figure 1.2

A schematic diagram of the α/β hydrolase fold (Ollis 1992). The

secondary structure is indicated by arrows for beta strands and cylinders for alpha helices.
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1MX1

1K4Y
Figure 1.3 Mammalian carboxylesterase structures. The four-letter code under each
structure is its code in the protein data bank.

8

mean square deviation (RMSD) over Cα carbons (Bencharit 2003; Bencharit 2003). Both
enzymes form trimers and the serine hydrolase fold exhibited by their structures includes
a central 15-stranded β sheet surrounded by several α helices and β strands.

Biological roles of carboxylesterases
The

specific

biological

functions

have

not

been

defined

for

many

carboxylesterases due to their wide substrate specificity. Carboxylesterases have been
found to play a role in processing endobiotic compounds, for example, in cholesterol
homeostasis (Becker 1994). Although cholesterol is essential in the structural integrity of
plasma membranes, it is toxic if present in excess. Thus, systemic trafficking of
cholesterol is crucial to the delivery and clearance of this compound. Fatty acids are
added to the 3-position of cholesterol by carboxylesterase to create cholesteryl esters,
which are packaged with high-, intermediate- and low density lipoproteins for systemic
delivery and clearance (Redinbo 2005).
Carboxylesterases are involved in drug metabolism. Many clinically useful drugs
containing ester groups are subject to catalysis by carboxylesterases (Tang 1995).
Carboxylesterases are essential in the hydrolysis of cocaine (Brzezinski 1994; Dean
1995), heroin (Brzezinski 1997), aspirin, procalin (Joly 1986), dipivefrin hydrochloride
(Nakamura 1992), carbonates (McCracken 1993), salicylates (White 1994), capsaicin
(Park 1994), palmitoyl-coenzyme A (Hosokawa 1987; Hosokawa 1990), haloperidol
(Nambu 1987), imidapril (Yamada 1992), pyrrolizidine alkaloids (Dueker 1992; Dueker
1992; Dueker 1995) and steroid (Lund-Pero 1994). Therefore, strategies to modulate the
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levels of the drugs such as cocaine and heroin in patients who have overdosed on these
substances are proposed (Kamendulis 1996; Pindel 1997). For example, human
carboxylesterase 1 can convert cocaine into benzoylecgonine, a non-toxic derivative. This
approach is especially useful for those cases where drug levels are extremely high and
would result in significant clinical problems that cannot be resolved by standard
emergency hospital care (Redinbo 2005).

The applications of carboxylesterases
Carboxylesterases are important enzymes in the hydrolysis and detoxification of
numerous peptides and drugs. Carboxylesterase-mediated hydrolysis of esters has been
used to design several ester-containing drugs including development of the
chemotherapeutic agent CPT-11 (Senter 1996; Kojima 1998) 10-hydroxycampothecin
fatty acid esters (Takayama 1998), and the drug lovastatin for the activation of the blood
cholesterol (Tang 1995).
The main application of microbial carboxylesterases is in biocatalysis, especially
in organic compound synthesis. The best studied enzyme is the carboxylesterase NP (NP
from naproxen, a non-sterodial anti-inflammatory drug) from Bacillus subtilis (Quax
1994). NP esterase is used in resolution of (R, S)-naproxen methylester and (R, S)ibuprofen methylester. Another enzyme used in organic synthesis is an esterase from A.
globiformis, which is used in the synthesis of (+)-trans-(1R, 3R)- chrysanthemic acid, an
important precursor of pyrethrin insecticides (Nishizawa 1995). Carboxylesterases can
also be used in the chemo- or regioselectivity reaction such as the release of ferulic acid
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from plant cell wall polysaccharides such as pectin or xylan (Falconnier 1994; LesageMeessen 1996; Gasson 1998). Microbial carboxylesterases are involved in the catabolism
of aryl esters, as shown by the example of an enzyme from Acinetobacter sp. that releases
an acid from benzyl esters (Jones 1999). p-nitro-benzyl benzyl esterase from Bacillus
subtilis is used to remove protecting groups in the synthesis of the antibiotic Loracarbef
(Zock 1994).
Carboxylesterases play important roles in prodrug activation. In the majority of
esterase-mediated reactions, the drug compounds are inactivated by esterases. While, in
the reaction of hydrolysis of prodrugs CPT-11 and capecitabine, the ester groups are
removed to improve their water solubility, resulting in elevated antitumor activity
(Kunimoto 1987; Bajetta 1996; Danks 1998; Matsuzaki 1998; Potter 1998). Therefore,
these carboxylesterases have a potential role in cancer gene therapy.

Cancer gene therapy
Several strategies have been used in cancer gene therapy. One major strategy is
correction of the genetic defect in tumor cells and another is killing the tumor cells.
Corrective gene therapy may not be a practical approach because most tumor cells
contain multiple genetic mutants. Gene replacement for cancer would require correcting
multiple oncogenes in every tumor cell since any nontransduced cells would continue
rapid replication. Therefore, cancer gene therapy has expanded the range of transgenes to
include those with ability to confer selective cytotoxicity to transduced tumor cells. The
purpose of most cancer gene therapy strategies is to kill tumor cells instead of restore
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their normal phenotype (Aghi 2000). Therapeutic transgenes that have been utilized
include those that (1) correct the primary genetic defect in many cancer cells. An
example is the restoration of wild type of tumor suppressor gene p53 expression using a
retroviral vector (Roth 1999); (2) enhance the immune response by transferring genes that
encode cytokines IL-2 and γ-IFN (Foa 1992; Watanabe 1992); (3) transfer of genes
conferring chemotherapy resistance into bone marrow or peripheral blood stem cells in
order to allow high dose of chemotherapy to be given, e. g. transfer of multidrug
resistance gene that encodes P-glycoprotein (DelaFlor-Weiss 1992); (4) transfer of genes
encoding enzymes or active enzymes directly to tumor sites to activate prodrugs (Habib
2001).

The role of carboxylesterases in CPT-11 gene therapy
Carboxylesterases have been evaluated for activation of prodrug CPT-11
(Irinotecan) in cancer gene therapy (Tsuji 1991; Satoh 1994; Senter 1996). CPT-11 is a
prodrug that can be activated by a carboxylesterase to generate SN-38 (7-ethyl-10hydroxycamptothecin), a topoisomerase I poison (Figure 1.4). Irinotecan is a watersoluble derivative of camptothecin, an alkaloid originally extracted from the Chinese tree
Camptotheca acuminata. CPT-11 has shown significant anti-tumor activity in human
tumor xenograft models. So far, irinotecan has been used in the treatment of different
types of cancers such as colorectal cancer (Rothenberg 2003), gastric cancer (Comella
2002), lung cancer (Ichiki 2003), cervical cancer (Chitapanarux 2003), ovarian cancer

12

Figure 1.4 Two steps of activation of prodrug CPT-11 to topoisomerase poison SN38 and 4- piperidino-piperidine (4PP) by carboxylesterase (Bencharit 2002).
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(Bodurka 2003), breast cancer (Agelaki 2003), head and neck cancer and brain tumors
(Koukourakis 1999; Friedman 2003).
CPT-11 is poorly activated in humans, thus this suggests the potential for the
development of an enzyme prodrug therapy (Danks 2004). Such a strategy allows the
enzyme to selectively activate inactive prodrugs to produce specific toxicity in desired
cell types. For CPT-11 activation, rabbit carboxylesterase (rCE) is considered the most
efficient enzyme and is ~5 fold and ~1000 fold more efficient than human intestine
carboxylesterase (hiCE) and human carboxylesterase (hCE), respectively (Potter 1998;
Danks 1999; Danks 2004). Two different approaches can be applied in this
Carboxylesterase/CPT-11 therapy (Figure 1.5).
Viral-directed enzyme prodrug therapy (VDEPT) is a technique that involves
physical delivery of a gene encoding a foreign enzyme to tumor cells where prodrugs can
be activated after expression of that enzyme (Xu 2001). Transfer of genes is generally
facilitated by a vector, which is either viral or non-viral. The ideal vector for gene
transfer would be safe and easy to prepare in large quantities. It would be efficient to
deliver genetic material and specific for its target, and not recognized by host immune
system (Habib 2001). Several viruses have been used for VDEPT, including retroviruses,
adenoviruses, herpes simplex virus (HSV), adeno-associated virus, lentivirus, and
Epstein-Barr virus (EBV). Retroviruses are used widely and have been utilized in 80 %
of gene therapy protocols. They can be integrated into genome and can give rise to stable
expression (Habib 2001). The main disadvantage associated with a retrovirus vector is
that the retrovirus can only target dividing cells, whereas most tumor cells are slowly
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dividing, so this results in a low transduction rate (2-10%) (Hamstra 1999). Vector
targeting is usually affected by direct injection into tumor tissues, but the efficiency is
very low. In order to increase the efficiency, the bystander effect has been utilized in
VEDPT. The Bystander effect is that activated drug can act not only on transduced cells
but also on nontransduced cells. This bystander effect requires cell–to- cell contact or
facilitation by drug diffusion or extracellular activation to target neighboring tumor cells.
Designing a secreted form of genes whose products can be secreted outside of cells is one
of the strategies that has been utilized in VEDPT (Howard B 1994). Several viral vectors
have been applied to achieve delivery of the cDNA encoding the carboxylesterases to
tumor cells (Kojima 1998; Kojima 1998; Wierdl 2002; Oosterhoff 2003; Oosterhoff
2005). A replication-deficient adenoviral vector Ad.C28-sCE2 containing a fusion gene
encoding a secreted form of human liver CE2 has been designed to target to the surface
antigen epithelial cell adhesion molecule (EpCAM) that is highly expressed on most
colon

carcinoma

cells

(Oosterhoff

2005).

They

demonstrated

that

active

carboxylesterases were expressed and secreted in Ad.C28-sCE2-transduced colon
carcinoma cells and bound specifically to EpCAM-expressing cells. The secreted
carboxylesterases allow the activated drugs to act not only on transduced cells but also on
nontransduced cells. Therefore, Ad.C28-sCE2 provides a promising approach for the
treatment of colon carcinoma. Wierdl et al developed an adenoviral vector expressing
intracellular rabbit carboxylesterase. After transduction, the virus produces very high
levels of CE activity in a panel of human tumor cell lines and results in marked
sensitization to CPT-11 for all of the transduced cells (Wierdl 2002).
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Figure 1.5 Two different approaches, Viral-directed enzyme prodrug therapy
(VDEPT) and Antibody-directed enzyme prodrug therapy (ADEPT), could be
utilized in carboxylesterase activating prodrug CPT-11 (Redinbo 2005).

16

An alternative approach is antibody-directed enzyme prodrug therapy (ADEPT).
In ADEPT, selectivity for a target is achieved by an antibody (Ab) in an Ab-enzyme
conjugate that binds to an antigen that is only expressed on the surface of tumor cells. In
the first step, antibody-enzyme conjugates are administrated and accumulate at the tumor
site. Enough time is allowed for clearance of the conjugate from blood and normal
tissues. In the second step, a nontoxic prodrug is administrated, which can be activated on
the surface of tumor cells and diffuse inside tumor cells. The advantage of this approach
is that not all tumor cells would be required to bind the antibody because drugs released
by the enzyme could diffuse to neighboring cells that are not expressing the antigen.
Also, in ADEPT, a single molecule has the potential to cleave many prodrug molecules.
The main drawback of ADEPT is that the Ab-enzyme conjugates can elicit the immune
response, which can prevent the administration of repeated doses of the conjugate. This
method has been applied in the activation of CPT-11 using hiCE and rCE against a
melanoma tumor model (Senter 2001). However, little success was achieved by this
method. This could be due to several factors including the loss of the enzyme activity
after coupling to the antibody, the low affinity of antibody to antigen, or relatively
inefficient activation of the drug. Increasing enzyme specificity or activity will help
improve this approach for cancer therapy (Redinbo 2005).

Protein Crystallography
Several mammalian and bacterial carboxylesterase structures have been
determined as described earlier (Figure 1.1& 1.3). Knowing their structures can help
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better understand their functions and explore their potential applications. For example,
knowledge of the structure of the starting protein is central to a rational way to redesign
the protein function. X-ray crystallographic determination has been the most extensively
used approach to obtain three-dimensional structures of various enzymes. Under certain
conditions, protein molecules form crystals. The crystal is an orderly three dimensional
array of molecules, held together by various noncovalent interactions including hydrogen
bonds, salt bridges, and hydrophobic interactions. Figure 1.6 depicts an example of
lysozyme crystals. X-ray scattering from a single molecule will be very weak and will not
be detected above the noise level, which includes scattering from the air and water. A
crystal has a huge number of molecules arranged in the same or a related orientation, so
that the scattering waves from all the molecules can add up together to reach a
measurable level. Thus, a crystal can act as an amplifier.
A crystal consists of an array of unit cells. Each unit cell is designated by six
parameters: the length of three unique edges (a, b and c) and three unique angles (α, β,
and γ). The unit cell is the smallest unit, which can build up the whole crystal by a
symmetric relationship. Determining crystal symmetry is usually the first step in data
collection and analysis (Rhodes 2000).
There are a number of potential bottlenecks in determining a crystal structure
such as growing diffraction quality crystals, finding a cryoprotectant and phase
determination, but growing a useful crystal can be the most serious one. There is no
general protocol for crystallizing proteins. The crystallization conditions vary from one
protein to the other. Even a single mutation and the addition of a small ligand can result
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Figure 1.6 Lysozyme crystals (Grown by Sonia Iyer in Dr. Weber’s lab)
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in a dramatic change of crystallization condition. Crystallization could be affected by
various factors such as protein concentration, temperature, pH, buffer, and salt. Finding
the exact conditions to produce good crystals of one specific protein often requires many
trials. Sometimes crystallization can be achieved by efforts of many years. By far the
most popular technique for crystallization is vapor diffusion. Hanging drop method under
the category of vapor diffusion is frequently used (Figure 1.7). In this method, a droplet
containing purified protein, buffer and precipitate is allowed to equilibrate with a
reservoir containing the precipitate in higher concentrations. Usually a few microliter of
purified protein is mixed with an equal amount of the reservoir solution. This solution is
suspended as a droplet underneath a cover glass, which is sealed on the top of the
reservoir. Because the precipitate concentration in the drop is about 50 % of that in the
reservoir, water vaporizes from the drop and transfers to the reservoir. When the system
comes to equilibrium, the net transfer of water ceases. If the precipitant concentration in
the drop increases to the level optimal for crystallization, protein molecules will be
crystallized (Rhodes 2000).
After obtaining a reliable source of suitable crystals, data collection can begin.
First, crystals must be positioned between an X-ray source and an X-ray detector. The
classical method of mounting crystals is to transfer them to a fine glass capillary along
with the mother liquor. In recent years, crystallographers have been able to take
advantage of collecting X-ray data of crystals at very low temperature, for example liquid
nitrogen (boiling point -196 ℃). Theoretically, lowering the temperature should increase
molecular order in the crystals and improve diffraction data quality. However, practically,
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Figure 1.7 Hanging drop method is a common used approach in crystallization.
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freezing crystals directly will result in damage due to formation of ice crystals.
Crystallographers have developed a technique for flash freezing crystals in the presence
of chemical agents called cryoprotectants, such as glycerol, small molecular weight
polyethylene glycol, sugar, oil. However, searching for a suitable cryoprotectant can be
another bottle-neck in the way of solving crystal structures due to the fragile nature of
protein crystals and the lack of a general protocol for this procedure (Rhodes 2000).
The crystal diffracts the source of X-ray beam into discrete directions, shown as
distinct spots (reflections) on the detector. Generally, the goal of data collection is to
maximize the data resolution and completeness with the shortest time. Usually the data
collection strategy is guided by the information of crystal symmetry, the unit cell
parameters, the crystal orientation and the resolution limit obtained from a few crystal
diffraction images in the initial trials.
The determination of protein structure by X-ray crystallography requires not only
crystallizing the proteins and experimental collection of diffraction data as intensities of
diffracted X-rays scattered from a protein crystal but also the phase angle. The intensity
and phase data can be transformed using the Fourier Transform equation to produce a
three-dimensional visualization of the scattering matter, which is called the electron
density map. But what we measure in the experiment is the number of X-ray photons in
each reflection. There is no practical way of measuring the relative phase angles of
different diffracted spots experimentally. The number of photons gives the intensity,
which is proportional to the square of the amplitude of the diffracted wave. But the phase
has been lost.
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The Phase problem is one of the most difficult problems in crystallography.
There are three commonly used strategies for determining accurate phases, namely,
multiple isomorphous replacement, multiple wavelength anomalous dispersion and
molecular replacement. The isomorphous replacement is achieved by comparison of the
diffraction data from two crystals, which differ because one or more strong scattering
centers exist in one crystal and are absent in the other. Usually a heavy metal ion or a
heavy metal compound, which can bind tightly to one or more sites of the protein
molecule, was directly added into crystallization solution or “soaked” into crystals. In
most cases, a protein is first crystallized in the absence of heavy atoms. The crystals
without the heavy atoms may be referred to as the parent or native form, and a crystal
including the heavy atom may be called the derivative. The word isomorphous means that
the parent and derivative crystals have the same unit cell dimensions and symmetry. The
binding of heavy atom ions or compounds usually disturbs the structure including
distorting the surrounding protein structure and probably forcing some solvent out of the
crystal, so isomorphism is never perfect. The isomorphous replacement method is based
on the theory that the scattering by a derivative crystal, containing heavy atoms is the
sum of the scattering by the parent crystal and the scattering by the added heavy atoms. It
usually requires at least two derivatives to determine the phase angles (Blow 2002).
The multiple anomalous dispersion method, which was developed later, is now
frequently used in phase determination. It provides extra phase information through the
violation of Friedel's law. The integers h, k, and l are used to identify each of the
diffracted waves forming the diffraction pattern. In the normal diffraction, a pair of
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reflections h, k, l and –h, -k, -l have the same structure amplitude and the phases have the
opposite sign. This is known as Friedel’s law. But at a wavelength close to the absorption
edge of an atom, the scattering violates the Friedel’s law. The heavy atom structure
factors FH (h,k,l) and FH (-h,-k,-l) have the same magnitudes, but they do not have the
opposite phases. The anomalous scattering method is based on the idea that the total
scattering by the structure is the sum of the normal scattering and the anomalous
scattering. But the anomalous scattering has the opposite effects on Friedel-related
reflections. Phase information can be obtained from measurement of the total scattering
for each member of the Friedel pair (Blow 2002). Anomalous scattering effects are
smaller than those obtained by isomorphous replacement, but the measurement is more
accurate because the diffraction data was collected on the same crystal. Useful anomalous
scatters can be far lighter than the heavy atoms used for macromolecular isomorphous
replacement. From iron (Z = 26) to palladium (Z = 46) the K absorption edges are at
convenient wavelengths. The K absorption of selenium (Z = 34) at 0.98 Å is easily
accessible in synchrotron radiation. Selenomethionine has similar chemical properties to
methionine and similar shape and volume. Cohen and Cowie first discovered that the
E.coli strain, which is auxotrophic for methionine, can grow in the medium containing
selenomethionine (Cowie 1957). Later, Hendrickson and co-workers found that selenium
is a very useful anomalous scatterer and they solved the structures of selenobiotyl
streptavidin (Hendrickson 1989) and of selenomethionyl proteins (Yang 1990).
The Molecular replacement method determines the orientation and position of a
molecule in the unit cell using an existing solved structure as a search model. The search
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and the target molecule must have reasonable sequence identities (>>25%) for this to
succeed. Generally there are two steps in this method known as rotation and translation
function (Blow 2002).
Model building is the next step where the electron density map is interpreted in
terms of a set of atomic coordinates. It is very straightforward in the case of molecular
replacement because many atoms have been positioned. However, in the case of the
multiple isomorphous replacement and multiple wavelength dispersion methods, we
simply have the electron density map. Normally, a protein backbone will be fit into the
density first and then the side chains of protein will be inserted based on the protein
sequence. The amount of the detail depends on the resolution and the quality of the
phases. Often the regions of high flexibility are not visible at all due to disorder.
Automated procedures using software such as ArpWarp (Lamzin 1993) to fit maps are
successful for data at higher resolutions (usually < 2 Å).
After we obtain a model from an electron density map and have interpreted it, the
next task of improving the interpretation is structural refinement, in which the atomic
model is adjusted to improve the agreement with the measured diffraction data. In
structural refinement, the measurement of discrepancy between the X-ray structure
factors calculated for the model structure |Fcal| and the observed intensities |Fobs| is
defined as an R factor:
R=

∑

h

Fobs − Fcal

∑

h

Fobs

(1)
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The purpose of structure refinement is to get the lowest R factor consistent with correct
geometry and interpretation of the electron density maps.

Structure-based protein engineering
Many proteins, especially enzymes, become therapeutic and commercial targets.
Most of the time, enzymes isolated from organisms do not fulfill the specific demands of
their therapeutic uses and industrial applications. To improve the properties of proteins or
enzymes for different purposes, protein engineering concepts have been developed. Two
main approaches, directed evolution and rational design, are utilized in protein
engineering (Svendsen 2004; Zhao 2004).
Directed evolution has emerged as a powerful approach for improving enzyme
properties and has been widely used in engineering many enzymes (Farinas 2001;
Altamirano 2002). Proteins in nature have evolved to perform specific biological tasks
through selective pressures. They are generally not optimized for nonnatural applications.
For instance, as potential chemical catalysts, they often are not stable, have low
specificity or low catalytic efficiency. Similarly, as potential therapeutic agents, natural
proteins often have low efficiency and low stability. As a result, naturally occurring
proteins have to be tailored in the laboratory to increase specificity and stability.
Structure-based rational design does not always result in success due to our limited
knowledge of protein folding, structure, function and dynamics. In comparison, directed
evolution does not always require any structural information and can often solve a protein
design problem in a short time. Sometimes, directed evolution can provide unexpected
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solutions for protein design problems. Random mutation and gene recombination are two
natural evolutionary processes that have been mimicked by directed evolution (Zhao
2004). Random mutations can be classified into four types: substitution, deletion,
insertion, and inversion. Gene recombination is a reassortment of a series of nucleotides
along a nucleic acid molecule, usually double-stranded DNA. The main differences
between random mutagenesis and gene recombination are elucidated as follows:
Random mutation starts from a single gene and creates a library of variants containing
point mutations or insertion/deletions. Whereas gene recombination usually starts from a
pool of variants from a single gene or a pool of closed related parent genes of different
origins and creates an exchange of sequence information among parent genes (Zhao
2004). Random mutagenesis by point mutation is the simplest way to create mutations.
Effective methods to introduce point mutations include chemical mutagens (Myers 1985),
UV radiation (Botstein 1985), mutator strains (Greener 1997), or error prone PCR (Leung
1989; Rice 1992). Among these methods, error prone PCR, introducing point mutations
based on inaccurate copying by DNA polymerase, is the most widely used method.
Random mutagenesis by insertion/deletion is another effective method to introduce
molecular diversity. Unlike point mutation, random mutagenesis by insertion or deletion
will alter the full length of the target gene. In contrast to random mutagenesis, gene
recombination is a “sexual” evolutionary process. Several approaches, both in vitro and
in vivo, have been developed to mimic nature’s recombination strategy. Usually in vitro
recombination offers higher recombination efficiency than in vivo approaches. DNA
shuffling starts from a pool of parent genes, which are first fragmented and then
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reassembled into full-length products by repeated cycles of overlap extension reaction.
Recombination occurs when fragments derived from parent genes prime each another
(Zhao 2004). Several other in vitro recombination approaches such as the staggered
extension process (StEP) method (Zhao 1998), random chimeragenesis on transient
template (RACHITT) (Coco 2001), family shuffling (Crameri 1998), degenerate
oligonucleotide gene shuffling (DOGS) (Gibbs 2001), sequence homologous-independent
protein recombination (SHIPREC) (Sieber 2001), and exon shuffling (Kolkman 2001) are
widely used (Svendsen 2004).
The alternative approach for protein engineering is structure-based rational
design. With the advent of structural genomics and the concomitant growth of PDB
(Protein Data Bank) (Berman 2000), it has become more likely that a protein engineer
will know the structure of their target protein or its homologs. The basic idea of rational
design is as follows: although there are many interactions that control the folding of a
protein or catalysis of a chemical reaction, a 3-D structure alone or in combination with
additional information, such as the biochemical and biophysical properties of a protein or
the structure of a homologous protein, together with understanding how the enzymes
work, will give ideas on how to improve selected protein properties (Lehmann 2004).
Many catalytic properties of an enzyme including pH activity profile, the specific
activity, the substrate specificity or enantioselectivity have been engineered to meet the
specific needs. To improve any of those properties by rational design, a high resolution
protein structure in complex with an inhibitor, a substrate or a product of the enzyme
reaction is generally required. If the protein-ligand complex structure is not available,
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computer modeling is an alternative way to model a substrate or a product into the active
site and provides ideas about which amino acids are important for substrate binding,
stabilizing the transition state of the reaction and for catalysis of the reaction (Svendsen
2004).

Est30 and Est55
Est30 and Est55 are two carboxylesterases isolated from Geobacillus
stearothermophilus (Ewis 2004). Est30 is a thermostable enzyme with optimal activity
for short chain acyl derivatives of length C4-C8 at a temperature of 70°C. Est30 showed
low sequence identity with the closest members in the eight previously classified families
of microbial carboxylesterases (Arpigny 1999). Therefore, Est30 represents a new
carboxylesterase family that includes enzymes from several pathogenic Gram-positive
bacteria. Est55 belongs to the microbial carboxylesterase Family VII. Sequence
alignment by BLAST (Basic Local Alignment Search Tool) (Altschul 1997) shows that
Est55 shares 32% identity and 48% similarity with rabbit carboxylesterase, which is
considered most efficient enzyme so far for activating prodrug CPT-11 (Danks 1999).
Est55 also showed higher enzymatic activity than rCE towards the same p-nitrophenyl
esters, which have a similar molecular diameter as CPT-11.
In this work, we describe studies of the structure, reaction mechanism, and
medical application of Est30 and Est55. The first chapter describes the structure
determination of carboxylesterase Est30 at 1.63 Å resolution using multiple anomalous
dispersion data. Est30 represents a new microbial carboxylesterase family. A 100 Da
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tetrahedral ligand was observed to be covalently bound to the side chain of catalytic
residue Ser94. This tetrahedral ligand was deduced to be propyl acetate, and represents
the first tetrahedral intermediate in the reaction mechanism. Therefore, this Est30 crystal
structure will help understand the mode of action of all enzymes in the serine hydrolase
superfamily. In the second chapter, the main focus is on the structure and reaction
mechanism study of carboxylesterase Est55. The Est55 structure was determined by the
molecular replacement method at 1.58 Å. An oxidized Cys408 was observed in one of
loops located in the active site of Est55 structure. This loop can mimic an “inhibitor” to
block the active site of Est55. Mutational analysis was used to explore the role of Cys408
in the Est55 enzymatic activity toward p-nitrophenyl substrates. The third chapter
describes the potential applications of Est30 and Est55 in cancer therapy.
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CHAPTER 2

Crystal Structure and Reaction Mechanism of A Thermostable Carboxylesterase
Est30 from Geobacillus stearothermophilus

CONTENTS
I. INTRODUCTION…………………………………………………………...

31

II. MATERIALS AND METHODS…………………………………………..

33

Expression and purification of recombinant Est30…………………...
Mass spectrometry……………………………………………………..
Crystallization………………………………………………………….
X-ray data collection…………………………………………………...
Structure determination………………………………………………...
Model refinement………………………………………………………
Sequence analysis……………………………………………………...
Structural analysis……………………………………………………...
DNA sequence analysis and accession numbers……………………….

33
34
34
35
36
36
37
37
38

III. RESULTS and DISCUSSION…………………………………………….

39

Crystallization…………………………………………………………
Overall structure……………………………………………………….
Catalytic triad………………………………………………………….
Est30 contains a tetrahedral reaction intermediate…………………..
Substrate binding pocket………………………………………………
Subunit interactions in the dimmer……………………………………
Comparison with Est30-HEPES complex…………………………….
Comparison of Est30 with other microbial carboxylesterases………...

39
43
47
49
53
54
54
55

31

I. INTRODUCTION
Carboxylesterases are ubiquitous enzymes with important physiological,
industrial and medical roles in the synthesis and hydrolysis of stereospecific compounds,
including the metabolic processing of drugs, and antimicrobial agents (Krish 1971;
Takayama 1998; Bornscheuer 2002). Carboxylesterases (carboxylic ester hydrolase, EC
3.1.1.1) are members of the α/β hydrolase family. They hydrolyze short chain aliphatic
and aromatic esters and are inhibited by low concentrations of organophosphorus
compounds (Krish 1971). The biochemical properties and industrial applications of
microbial carboxylesterases have been reviewed recently by Bornscheuer (Bornscheuer
2002). Carboxylesterases exhibit high regio- and stereospecificity, require no cofactor in
the reaction, and are stable and active in organic solvents (Moher 1989; Bornemann
1992; Margolin 1993). The hydrolysis reaction is believed to proceed through several
steps including formation and dissociation of two tetrahedral intermediates (Satoh 1998).
Microbial carboxylesterases have been classified into eight families based on their
sequences (Arpigny 1999). However, the molecular structures are known for only a few
bacterial carboxylesterases. Crystal structures are available for two members of the
hormone-sensitive lipase (HSL) family (Family IV), (De Simone 2000; De Simone 2001)
and one carboxylesterase from the Family VI (Kim 1997). These structures have a typical
α/β hydrolase fold (Ollis 1992; Heikinheimo 1999; Nardini 1999) with a central parallelstranded β sheet surrounded by α helices on both sides. The enzymes contain the same
catalytic triad (Ser-Asp-His), with the serine located in a sharp turn between a β strand
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and α helix that is known as the nucleophile elbow. The major structural differences are
in the conformation of the substrate binding pockets.
The esterase gene est30 was recently isolated from the genomic library of the
Gram-positive bacterium Geobacillus stearothermophilus and cloned and expressed in E.
coli (Ewis 2004). The est30 gene encodes 247 amino acids with a calculated molecular
mass of 28257 Da. Est30 was shown to be active as a dimer with optimal activity for
short chain acyl derivatives of length C4-C8 at a temperature of 70°C. Est30 showed no
more than 21% sequence identity with the closest members in the eight previously
classified families of microbial carboxylesterases (Arpigny 1999). Therefore, Est30
represents a new carboxylesterase family that includes enzymes from several pathogenic
Gram-positive bacteria. This chapter describes the crystallization and preliminary
diffraction data for Est30 (Liu 2003) and the crystal structure of Est30 with a covalent
ligand that represents a trapped reaction intermediate (Liu 2004). This structure will help
to understand the reaction mechanism for this widespread class of enzymes.
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II. MATERIALS AND METHODS

Expression and purification of recombinant Est30
The coding sequence of est30 amplified by PCR was cloned into the pBAD-HisA
vector (Invitrogen) and the resulting recombinant plasmid was designated pHE30.
Escherichia coli Top10 (Invitrogen) harboring pHE30 was induced for 4 h by 1 mM
arabinose in 1 liter culture and then harvested at 5000 g for 15 min at 277 K. The cell
pellet was suspended in 40 ml of hypertonic solution consisting of 20 mM Tris-HCl pH
7.5, 2.5 mM EDTA and 20% sucrose. The suspension was incubated on ice for 30 min
and vortexed every 10 min. Cells were removed by centrifugation at 13 000 g for
20 min at 277 K and the cell pellet was resuspended in 60 ml of 20 mM Tris-HCl pH
7.5, 2.5 mM EDTA (hypotonic solution) and further incubated on ice for 30 min with
intermittent vortexing every 10 min. Cells were removed by high-speed centrifugation at
22 000 g for 20 min at 277 K and the supernatant applied to a Pharmacia Q-Sepharose
Hiload 26/10 HP that was equilibrated with 50 mM Tris-HCl pH 8.0. The column was
washed with 150 ml of the equilibration buffer to remove unbound proteins, followed by
a linear gradient to 50 mM Tris-HCl pH 8.0 and 1 M KCl. The esterase peak eluted at
0.65 M KCl. Fractions containing esterase activity were pooled (32 ml), concentrated to
5 ml by ultrafiltration and applied to a Sephacryl S 200 HR column (Pharmacia, 26/60).
The enzyme was eluted using 50 mM potassium phosphate pH 7.0 and 0.15 M NaCl.
The selenomethionine Est30 derivative (SeMet-Est30) was prepared following the
same protocol with some modifications. E. coli top 10 cells carrying the recombinant
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clone pHE30 were grown in M9 medium with 19 amino acids (40 µg/ml final
concentration) and selenomethionine (60 µg/ml final concentration) using glycerol as a
carbon source. SeMet-Est30 was purified under reduced conditions in order to avoid
oxidation of the selenium by adding 10-20 mM DTT to the purification buffers and
storing the protein under vacuum in each purification step.
Mass spectrometry
An electrospray-quadrupole/time-of-flight spectrometer (Waters Micromass QTOFTM micro, Waters Corporation, Milford, Massachustts, USA) was used to carry out
the mass spectrometric experiments in a positive mode. Nitrogen supplied by a nitrogen
generator (Model 75-72, Parker Balston, Haverhill, MA, USA) was used as the cone gas
at 50 L/hr, and as the drying gas heated to 150°C at a flow-rate of 450 L/min to evaporate
solvents in the spray chamber. Argon was used as the collision gas. The voltage settings
for the API electrospray interface were capillary, 2700 V; sample cone, 35 V; Extraction
Cone, 0.5V. The source temperature was at 80 oC and the desolvation temperature was at
150 oC. The sample at 2.5 mg/ml was diluted 10 times with 50 % MeOH containing 0.1
% formic acid. All solutions were continuously infused by means of a syringe pump at a
typical flow-rate of 5 µl min-1 into the electrospray probe. MassLynx (version 4.0)
software was used for instrument control, data acquisition and processing.

Crystallization
Purified native and SeMet-Est30 were dialyzed into Tris buffer at pH 8.0 and
were concentrated to 4.6 mg/ml and 2.5 mg/ml, respectively. Est30 was crystallized at
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room temperature by hanging drop vapor diffusion at 24 oC using 1 µl of protein and 1 µl
of mother liquor. Crystals were initially grown with 45-50 % ammonium sulfate pH 8.0,
Tris pH 7.5-8.1 or HEPES pH 7.5, MPD 8-12 %, and 0.1 % sodium azide as described
previously (Figure 2.1) (Liu 2003). During freezing it was found that the crystals
dissolved in all tested cryoprotectants except for high concentration of lithium sulfate.
These crystals showed disorder in the diffraction pattern; the spots were smeared and the
mosaicity was very high (more than 0.6). Therefore, different growth conditions were
tried. Finally, single native Est30 and SeMet-Est30 crystals were grown using lithium
sulfate as the precipitant. The optimum conditions were 70 % lithium sulfate, 5 %
PEG400, 5 % Dioxane, and 100 mM HEPES pH 7.5.

X-ray data collection
Crystals were mounted on a nylon loop and frozen directly in liquid nitrogen. Xray diffraction data were collected on a MAR CCD 165 detector for SeMet-Est30 crystals
and a MAR CCD 225 detector for native crystals at the SER-CAT beam line of the
national synchrotron light source at the Advanced Photon Source.

Selenium X-ray

multiplewavelength anomalous diffraction (MAD) data with crystal to detector distance
of 130 mm and oscillation angle of 0.5° were collected at four wavelengths: 0.9792 Å,
(peak), 0.97933 Å (inflection point), and 0.971602 Å (high energy remote) and 0.987072
Å (low energy remote) (Table 1). Two 180° datasets of high and low resolution were
collected from a native crystal.
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Structure determination
The X-ray data were integrated using the HKL2000 program (Otwinowski 1997).
The space group was orthorhombic C2221 with cell dimensions of a = 55.476 Å, b =
58.474 Å and c = 179.163 Å, and contained one molecule per asymmetric unit. Phasing
and automatic structure tracing were tried using the SOLVE/RESOLVE package
(Terwilliger 1997; Terwilliger 2001) with scaled but unmerged data. Eight of the ten
expected selenium sites were identified in residues 34, 74, 115, 119, 127, 153, 161, and
195 (except for the N-terminal residues 1 and 2) using the program SOLVE (Terwilliger
1997). RESOLVE was run to perform density modification and automated model
building (Terwilliger 2001). The partial model from RESOLVE containing 7 α helices
and 5 β strands was used as a starting point for automated model building and side chain
docking by ARP/WARP (Lamzin 1993). 90% of the structure was automatically traced
by ARP/WARP (Lamzin 1993). The subsequent manual building of one missing loop on
the surface of structure was performed using the graphics program O (Jones 1991).

Model refinement
Crystallographic refinement was initially carried out using the CNS package.
(Brunger 1998)Manual adjustments and rebuilding were performed using O and σAweighted electron density maps. After simulated annealing and B-group refinement, the
missing loop was built. Individual B factor refinement resulted in a model with Rfactor =
24.0 % and Rfree =26.5 %.
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The crystal structure of the Se-Met Est30 was used to solve the native Est30
crystal structure by molecular replacement using AMoRe (Navaza 1994) The native
crystal structure was refined in space group C2221 with one molecule per asymmetric
unit. SHELX 97 (Sheldrick 1997) was used to refine the structure with solvent and
anisotropic temperature factors. During refinement, the Fo-Fc difference Fourier map
showed positive electron density connecting with the catalytic residue Ser94, suggesting
a covalent bond modification of the Ser94. Therefore, the density was modeled with a
tetrahedral intermediate in the active site. The size of the intermediate was determined by
mass spectrometry. The structure was analyzed with PROCHECK (Laskowski 1993)

Sequence analysis
Sequence similarity

searches

were

performed

using

BLAST

at

(http://www.ncbi.nlm.nih.gov/BLAST) (Altschul 1997). Multiple sequence alignments
used the CLUSTALX and GENEDOC programs (Nicholas 1997; Thompson 1997)

Structural analysis
The native and SeMet-Est30 crystal structures were superimposed on all Cα
atoms using an implementation of the algorithm described in [Ferro & Hermans, (1977)]
(Ferro 1977). The structures of Est30 and the carboxylesterase from Pseudomonas
fluorescens were superimposed on all Cα atoms using the program ALIGN (Cohen
1997). Figures were generated with MolScript (Kraulis 1991) BobScript (Esnouf 1999)
and Raster3D (Merritt 1997).
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Protein Data Bank accession numbers
The coordinates have been deposited in the Protein Data Bank with accession
code 1TQH.
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III. RESULTS and Discussion
Crystallization
The recombinant Est30 from G. stearothermophilus was expressed and purified
for crystallographic analysis. The total yield of pure esterase was 6 mg per liter of
culture. The purified Est30 was judged to be in excess of 95% homogeneous. Crystals
were grown by hanging-drop vapor diffusion using ammonium sulfate as precipitant.
Under the optimal crystallization conditions, Est30 crystals appeared after 2 or 3 d and
reached maximum dimensions of 0.6 × 0.15 × 0.05 mm after one week. An example is
shown in Figure 2.1. The crystallographic statistics are summarized in Table 2.1. The
crystals diffracted to better than 2.0 A resolution. X-ray diffraction data were reduced in
space group C2221, with unit-cell parameters a = 55.83, b = 58.15, c = 179.65 A. Rmerge
was 0.038 for 17,449 independent reflections with a completeness of 85.1%. VM was
calculated to be 2.43 A3 Da-1 (Matthews 1968) and the solvent content was 0.49, which
suggested that there was one molecule of Est30 in the asymmetric unit. However,
crystallographic diffraction of crystals grown from this crystallization condition showed
high mosaicity (Figure 2.2A), which is not suitable for phase determination using either
isomorphous replacement or multiple anomalous dispersion method.

Different

crystallization conditions were tried and finally high quality diffraction data were
obtained from both native and SeMet-Est30 crystals grown from lithium sulfate (Figure
2.2B).
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Figure 2.1 Crystal of Est30 grown in 50% ammonium sulfate, 10% MPD, 0.1%
sodium azide, 100 mM HEPES pH 7.5 at room temperature. The size of this crystal is
approximately 0.3 × 0.17 × 0.05 mm.
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A

B

Figure 2.2 Diffraction pattern of Est30 crystals. Crystallographic diffraction of crystals
grown from ammonium sulfate as precipitate (A) and lithium sulfate as precipitate (B).

42

Table 2.1 Data collection statistics of crystals grown from ammonium sulfate as
precipitant
Space group

C2221

Resolution Å

1.99 (2.07-1.99)
a = 55.83, b = 58.15,
c = 179.65

Unit-cell parameters Å
No. reflections with I > 3 σ(I)
<I/σ(I)>

16997 (1182)
19.4 (7.6)

Independent reflections

17449 (1388)

Rmerge#

0.038 (0.112)

Completeness %

85.1 (69.4)

Redundancy
#

Rmerge =

4.8 (2.2)
.

43

Overall structure
The Est30 structure could not be solved by molecular replacement owing to the
lack of an available structure with homologous protein sequence. Multiple isomorphous
data or anomalous dispersion data were needed to obtain phase information. Halide soaks
were not successful. However, Est30 has two cysteine and ten methionine residues.
Therefore, SeMet-enriched protein was prepared for phase determination using the
multiple wavelength anomalous diffraction (MAD) method. The native Est30 crystal
structure was solved in space group C2221 using multiple anomalous dispersion (MAD)
phasing and automated tracing, and refined to an R-factor of 17.1% at 1.63 Å resolution.
The crystallographic statistics for data collection and refinement are shown in Tables 2.2
and 2.3. No density was visible for the N-terminal five residues. The Est30 structure
includes residues 6-247 with a covalent ligand on Ser94, as described later. The side
chains of residues Leu35, The114, Met127, Lys165, Met195, Glu207 and Glu220 were
modeled with alternate conformations. The solvent density was fit with two sulfate ions
and 153 water molecules (including full and half occupancy sites).
Est30 folds into two domains with the catalytic triad and substrate-binding site
located at the interface between the domains (Figure 2.3). The smaller domain consists of
three α helices B1’, D1’ and D2’ that form a cap over the active site. The larger domain
resembles the classical α/β hydrolase fold.(Ollis 1992) It contains a central sevenstranded β-sheet surrounded by six α-helices, αA (Ala30-Ser41), αB (Pro66-Asn82), αC
(Leu95-Gly104), αD (Leu164-Leu180), αE (Ser200-Glu207) and αF (Lys231-Ser244).
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Figure 2.3. (a) Overall structure of carboxylesterase Est30. Six α-helices A–F (red),
and seven β-strands 2–8 (green) are labeled using the nomenclature for the classical α/β
hydrolase fold(Ollis 1992), and the three cap helices are labeled B′1, D′1 and D′2. The
catalytic residues Ser94, Asp193, and His223 (cyan) are shown in ball and stick
representation. (b) Topology diagram of Est30. The secondary structure is indicated as
in (a); β-strands are shown as arrows, α-helices are presented as cylinders. The cap (cyan)
is composed of three helices unlike the typical α/β hydrolases. The catalytic triad residues
Ser94, Asp193, and His223 are indicated by black stars.
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Table 2.2 Data collection statistics of crystals grown from lithium sulfate as precipitant
MAD Data
Peak

Native

Inflection High energy Low energy
point
remote
remote

Wavelength Å

0.97920

0.97933

0.971602

0.987072

0.9997

Resolution (last shell) Å

50-2.0
(2.3-2.0)

50-2.05
(2.09-2.05)

50-2.0
(2.03-2.0)

50-2.4
(2.49-2.4)

50-1.63
(1.69-1.63)

Rmerge (last shell)
Unique Reflections
Redundancy
Completeness (last shell) %
<I/σ>

0.09 (0.37) 0.09 (0.39)) 0.07 (0.36) 0.06 (0.29) 0.16 (0.18)
20147

18778

20175

11571

35555

7.0

6.8

6.8

4.4

6.2

100 (100)

99.9 (100)

12.1

12.9

99.8 (99.6) 96.0 (83.4) 97.5 (90.5)
14.6

13.3

14.3
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Table 2.3 Crystallographic Refinement Statistics
Resolution range (Å) (last shell)

10-1.63 (1.70-1.63)

Rfactor /Rfree

17.14 / 22.79

No. residues

242

No. water molecules

153

No. sulfates

2

rms deviation from ideality
Bond length (Å)

0.008

Bond angles (deg.)

0.024

Ramachandran plot
Most favored regions (%)

92.4

Additional allowed regions (%)

7.6

Averaged B-values (Å2)
Main chain atoms

23.4

Side chain atoms

28.1

Covalent ligand atoms

31.7

Solvent atoms

35.1

All atoms

26.5
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The β-sheet of the typical α/β hydrolase fold consists of eight strands with the second β
strand antiparallel to the others. However, the first β strand of the typical α/β hydrolase
fold is missing from the Est30 structure. Therefore, the β-sheet of Est30 only has seven
strands (β2 - β8) with the N-terminal β2 strand antiparallel to the others.
The Est30 structure also differs from the classical α/β hydrolases in the presence
of the smaller cap domain comprising three helices. The existence of the cap has been
reported in the structures of carboxylesterases from the thermophile Alicyclobacillus
acidocaldarius and from archaeon Archaeoglobus fulgidus (De Simone 2000; De Simone
2001). However, the cap in Est30 lies mainly near the N-terminal end of the central β
sheet instead of near the C-terminal end of the β sheet as is observed in the other two
carboxylesterases. Also, the cap in the archaeon carboxylesterase is composed of 5 α
helices (De Simone 2001) instead of the three helices in Est30. Therefore, the cap
structure of Est30 is different from those of the other known bacterial carboxylesterase
structures.

Catalytic triad
The three dimensional structure of Est30 shows that the catalytic triad consists of
Ser94, Asp193, and His223 (Figure 2.4). Ser94 is in the conserved sequence Gly-X-SerX-Gly.(Brenner 1988) All three catalytic residues are located on the top of the C-terminal
β sheet. Ser94 is positioned at a sharp turn between β5 and helix αC that is called the
nucleophile elbow. The main chain φ and ψ angles of Ser94 are outside the favored
regions of Ramachandran plot (φ =57.7, ψ = -120.9), which is common for the
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Asp193
Ser94

His223

B

Gln189

Ser94

Asp193

2.7
2.7
3.2

3.4

3.1
2.8
Glu194

Leu95 oxyanion
2.8 hole
2.9
Phe25

His223

Met195

Figure 2.4 The active site region of Est30. (a) 2Fo−Fc electron density map contoured at
1.6σ. (b) Interacting residues. Interatomic interactions are shown in broken lines with
distances in Å. The negative charge of the oxygen atom of the tetrahedral intermediate
and the NH groups of Leu95 and Phe25 form an oxyanion hole (labeled in red).
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nucleophile in α/β hydrolases (Nardini 1999). The conformation of Ser94 is stabilized by
hydrogen bond interaction of the hydroxyl group with the side chain of His223. Asp193
and His223 are positioned at loops between β7 and αE and β8 and αF, respectively. A
network of hydrogen bonds stabilizes the side chains of Asp193 and His223 (Figure
2.4B). The OD1 atom of Asp193 has hydrogen bond interactions with ND1 in His223
and the NE2 atom in Gln189. The OD2 atom in Asp193 has hydrogen bond interactions
with ND1 of the His223 side chain, and the amides of Glu194, Met195 and Ile196.
Similar hydrogen bond networks are observed in the catalytic triad structures of other
carboxylesterases (Kim 1997).

Est30 Contains a Tetrahedral Reaction Intermediate
Unexpectedly, extra density was observed near the side chain of Ser94 (Figure
2.5). This density indicated that a tetrahedral ligand was covalently bound to the side
chain of Ser94. The existence of a covalent ligand was confirmed by mass spectrometry.
The Est30 sample was 28356 Da, or 99 Da more than the calculated protein mass. Two
tetrahedral intermediates are formed during the esterase reaction. The reaction
mechanism is considered to proceed through several steps as shown in Figure 2.6
(Bornemann 1992; Hakulinen 2000). Initially, the hydroxyl of the active Ser94 binds to
the substrate forming the first tetrahedral intermediate. The negative charge of the oxygen
atom of the intermediate is stabilized by hydrogen bond interactions in the oxyanion hole.
Then, the alcohol product is released and the acyl-enzyme complex is formed. His223
stabilizes the nucleophile oxygen of water, which attacks the carbonyl carbon of the
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Figure 2.5 Covalent ligand. Omit Fo−Fc electron density map contoured at 2.5σ.
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Figure 2.6 Possible reaction mechanism (Satoh 1998). Six intermediates in the Est30
reaction are shown. The reaction proceeds through the following steps. (1) Nucleophilic
attack to form the first tetrahedral intermediate. (2) Formation of the acyl–enzyme
complex. (3) Release of the alcohol product. (4) Nucleophilic attack forming the second
tetrahedral intermediate. (5) Release of carboxylate product.
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acetyl group of the substrate to form a second tetrahedral intermediate. Finally, the
carboxylate product is released from Ser94.
The two possible tetrahedral intermediates (Figure 2.6) of about 100 Da were
evaluated. Geometrical constraints and the X-ray data were consistent with the presence
of propyl acetate (101 Da) as the first tetrahedral reaction intermediate with the R group
of CH2-CH2-CH3. The omit map for the tetrahedral intermediate is shown in Figure 2.5.
The tetrahedral carbon, the three oxygens and the methyl carbon atoms were well defined
with atomic B factors similar to those of the protein atoms. Switching the positions of the
oxygen and methyl group resulted in difference density at the atoms, which confirmed the
geometry. The B factors increased along the flexible propyl group to give an average for
the ligand atoms of 31.7 Å2. The intermediate is stabilized by hydrogen bond interactions
with the amides of Phe25 and Leu95 in the oxyanion hole and with a water molecule, as
shown in Figure 2.4. The stable existence of the trapped tetrahedral intermediate suggests
that its dissociation is the rate limiting step for Est30. Consequently, the Est30 complex
provides important geometrical details for the reaction mechanism.
Est30 showed hydrolysis activity in the temperature range of 40-70 °C (Ewis
2004). Therefore, the reaction intermediate appears to have been trapped when the
temperature was reduced during the Est30 reaction at a higher temperature. No acyl esters
were added during protein expression, purification or crystallization. Hence, the substrate
is presumed to have bound during the expression in E. coli. At the 37 °C used for
bacterial growth the Est30 activity is 34 % of its maximum at 70 °C (Ewis 2004).
Therefore, it is possible that the reaction commenced during bacterial expression and the
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tetrahedral intermediate was trapped when the cells were harvested at 4 °C. Subsequent
purification and crystallization of Est30 occurred at room temperature, where the enzyme
activity is only 7 % of the maximum activity.

Substrate binding pocket
The putative substrate-binding cavity extends on both sides of Ser94 in a cleft
between the cap and the larger hydrolase domain. The propyl alcohol side of the substrate
lies within a larger, more exposed groove between the cap and the larger domain. The
groove extends to approximately 10-14 Å from Ser94 and could fit a longer, more polar
ligand. The groove is formed by hydrophobic side chains of Leu93, Val224 and Leu227
on one side, Gly24, Gly27 and the side chain of Asp31 at the base, and by the polar side
chains of Glu133, Tyr134, Glu137 and Arg141 from the cap on the other side. The ligand
atoms have van der Waals contacts with Gly24, Gly27, and Val224.
The acetate product would fit in a less exposed hydrophobic pocket of
approximately 8 Å wide and 8-10 Å long, consistent with the observed activity on acyl
chain derivatives of length C2-C12 (Ewis 2004). This pocket is formed by the loops of
residues 23-29, 191-199, 219-224, and helices αD and D2’. The hydrophobic side chains
comprising this pocket are Phe25, Thr26, Trp69, Leu95, Val98, Phe99, Pro118, Ile121,
Met127, Val131, Leu167, Leu170, Ile171, Met195, and Ile196. The side chains of
Met127 and Met195 showed two alternative conformations. Because Met195 is located
about 3.8 Å from the side chain of His223 (Figure 2.4) these two conformations might
have a role in substrate binding.
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Subunit interactions in the dimer
Est30 is catalytically active as a dimer in solution (Ewis 2004) The Est30
homodimer can be constructed from the 2-fold crystallographic symmetry. The residues
211 to 219 of the two C-terminal β8 strands lie antiparallel at the interface between two
subunits. Residues Asn202, Tyr205, Asn206 located on helix αE and Arg191 on strand
β7 also contribute to stabilizing the intermolecular packing. The side chains of several
residues are involved in intersubunit hydrogen bond interactions. There are intersubunit
hydrogen bonds of the side chains of Tyr205 with Asn202 and Trp217, the side chain of
Gln214 with the side chain of Glu219 and with the carbonyl oxygen and amide of
Trp217, the side chain of Arg191 with the carbonyl oxygen of Lys213. The dimeric
arrangement is similar to that of the carboxylesterase from the achaeon Archaeoglobus
fulgidus (De Simone 2001).

Comparison with Est30-HEPES Complex
Subsequent to solution of this Est30 structure the crystal structure of an inhibited
form of the Est30 dimer was deposited in the protein databank (PDB entry 1R1D) (Cuff).
This structure shows seleno-methionine-Est30 with 4-(2-hydroxyethyl)-1-piperazine
ethane sulfonic acid (HEPES) bound in the active site. The Est30-HEPES structure was
compared to the Est30-reaction intermediate structure. The two structures superimposed
with a root mean square difference of 0.33 Å on Cα atoms. Most of the residues forming
the substrate-binding site are in nearly identical positions in both structures, except for
the side chains of Leu95 and Lys122. The side chain of Lys122 has moved to interact

55

with the carbonyl oxygen of SeMet195, and the Leu95 side chain has moved away to
allow a water molecule to interact with the HEPES sulfate. Both the HEPES and the
tetrahedral intermediate interact with His223 (Figure 2.7). However, there was a small
change in position of the catalytic His223 (0.5 Å for Cα atom). The hydrogen bond
interaction between the side chains of His223 and Ser94 is 3.1 Å in the Est30-HEPES
structure and 2.7 Å in the Est30-tetrahedral intermediate complex, concurrent with the
small change in position of His223. The HEPES formed a hydrogen bond interaction with
Ser94 rather than the covalent linkage of the tetrahedral intermediate. This comparison
suggests that the HEPES is bound approximately in the position of the released alcohol
product.

Comparison of Est30 with other microbial carboxylesterases
The most interesting structural difference between the Est30 and the typical α/β
hydrolases is the presence of three helices forming a second small domain on the top of
the larger domain. This smaller domain forms a cap over the active site. The presence of
the cap has been reported in the structures of carboxylesterases from the thermophile
Alicyclobacillus acidocaldarius and from archaeon Archaeoglobus fulgidus (De Simone
2000; De Simone 2001) However, the cap in Est30 covers mainly the N-terminal end of
the central β sheet instead of the C-terminal end of the β sheet as observed in the other
two carboxylesterases. Another difference is that the cap in the carboxylesterase from
achaeon Archaeoglobus fulgidus is composed of 5 α helices (De Simone 2001) instead of
three in Est30. Therefore, the Est30 cap structure differs from those of the other known.
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3.1
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Figure 2.7 Comparison of Est30 complex with covalent ligand (green) and Est30HEPES complex (1R1D) (red). Hydrogen bond interactions with His223 are shown in
dashed lines.
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bacterial carboxylesterase structures. The cap is adjacent to the active site of the enzyme
and forms part of the substrate binding pocket. Therefore, the different cap structures
might contribute to the different substrate specificities.
The carboxylesterase from Pseudomonas fluorescens is the most similar
structurally to Est30 (Figure 2.8), although the two proteins share very low sequence
identity (18.3%) (Kim 1997). Both proteins have seven β strands surrounded by six α
helices in the larger domain. Est30 has a relatively large cap, consisting of the small B1’
helix and the two large helices D1’ and D2’, that lies over the N-terminal strands of the
central β sheet. However, the carboxylesterase from P. fluorescens forms a smaller cap
consisting of a winding loop and two β strands after β4 that covers the C-terminal strands
of the β sheet. Superimposing these two structures after removing the cap gave a RMSD
value of 1.75 Å, which indicates that the typical α/β hydrolase fold is conserved among
bacterial species. Both enzymes share a similar active-site cleft formed by six loops at
the C-terminal ends of the parallel β strands. The P. fluorescens carboxylesterase is active
on acyl chains from C2 to C10 in length, compared to C2 to C12 for Est30. These
differences in substrate specificity are consistent with the presence of a more open
substrate-binding site in Est30, as well as differences in the cap structures.
The catalytic triad displays virtually indistinguishable geometry in both enzymes.
The RMSD values for the residues of the catalytic triad (Ser94/Asp193/His223 in Est30
and Ser114/Asp168/His199 in P. fluorescens) are 0.88 Å, 0.94 Å and 1.32 Å,
respectively. Also, P. fluorescens has similar interactions between catalytic triad residues
to those in Est30. The OD1 and OD2 atoms in Asp168 have hydrogen bond interactions
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Figure 2.8 Superposition of Est30 and closest other esterase structure from P. fluorescens (1AUO) in a stereoview. Est30
is colored in red and 1AUO is colored in green.
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with ND1 atom in His199. The distance between the Ser114 OG atom and the NE atom
of His199 (2.76 Å) of P. fluorescens is similar to that between the corresponding residues
in Est30 (2.72 Å), which suggests that the interactions among the catalytic triplet residues
are highly conserved among the carboxylesterases.
The Est30 sequence was compared to the sequences of members of the related
enzyme families. Microbial lipases and carboxylesterases have been classified into eight
families based on their sequences (Arpigny 1999). The differences between the
carboxylesterases and lipases lie mainly in their substrate specificity. Carboxylesterases
hydrolyze at least partly soluble small ester-containing molecules, while true lipases work
on water-insoluble long chain fatty acids. Est30 was identified as a carboxylesterase
because it has maximal activity towards short chain acyl derivatives of length C6,
decreased activity towards the longer C8 to C12 derivatives, and undetectable activity
towards C14 and C18 chains (Ewis 2004). Est30 is closest to family VI enzymes in the
classification of Arpigny (Arpigny 1999). This family of enzymes has molecular weight
in the range 23-26 kDa and the active form is a dimer. Est30 is also active as a dimer with
the higher molecular weight of 30 kDa for a monomer. The family VI enzymes, like
Est30, have no activity towards long-chain triglycerides. The family VI enzymes show a
classical α/β hydrolase fold unlike the modified fold with a seven-stranded β sheet
observed for Est30. Moreover, Est30 showed only 10-21% sequence identity with family
VI members. Most significantly, Est30 has none of the conserved sequence motifs
observed for this family (Arpigny 1999). Instead, Est30 has high sequence identity (7697%) with carboxylesterases in other Gram-positive strains, such as Bacillus subtilis,
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Bacillus cereus, and Bacillus anthracis (Figure 2.9) (Kunst 1997; Read 2002; Ivanova
2003). This analysis suggests that Est30 is a member of a new enzyme family. The
sequence similarities suggest that all members of this family have a similar tertiary
structure, including the 3-helix cap of Est30. The hydrophobic specificity pocket for
substrate consists of mostly identical residues in the family members, except for two
residues indicated on helix D1’ and one on αD (Figure 2.9). The residues in D1’ are
Met127 and Val131 in Est30, but the equivalent positions have Val or Leu, and Ile or
Phe, respectively, in the other enzymes. Leu167 of Est30 is substituted by Val in the
esterase from O. iheyensis. These differences in the hydrophobic side chains may alter
the substrate specificity.
The crystal structure of Est30 provides fundamental insights into the reaction
mechanism and substrate specificity of this new family of carboxylesterases. Moreover,
the detailed geometry of the tetrahedral intermediate will help understand the mode of
action of the broad category of physiologically important enzymes in the serine hydrolase
superfamily. The Est30 structural data will be valuable for design of new transition-state
analog inhibitors for a wide variety of processes catalyzed by these enzymes.
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Figure 2.9 Sequence alignment of Est30 and related proteins. Est30 showed 76-97% sequence identity with
carboxylesterases from Geobacillus thermoleovorans, Bacillus anthracis, Bacillus cereus, Bacillus halodurans, and
Oceanbacillus iheyensis. The secondary structure of Est30 is indicated by green arrows for beta strands, and red cylinders for
alpha helices. The catalytic triad residues (Ser94, Asp193, and His223 in Est30) are indicated by large red asterisks. The
residues forming the hydrophobic specificity pocket are indicated by small black asterisks. These residues are Phe25, Thr26,
Trp69, Leu93, Leu95, Val98, Phe99, Pro118, Met127, V131, Leu167, Leu170, Ile171, Met195, Ile196, Val224 and Leul227 in
Est30.
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I. INTRODUCTION
Carboxylesterases are important enzymes in the hydrolysis and detoxification of
numerous peptides and drugs. Carboxylesterase-mediated hydrolysis of esters has been
used to design several ester-containing drugs including the development of
chemotherapeutic

agents

CPT-11

(Senter

1996;

Kojima

1998),

and

10-

hydroxycampothecin fatty acid esters (Takayama 1998) and the drug lovastatin for the
activation of the blood cholesterol (Tang 1995). Carboxylesterases are also essential in
the hydrolysis of cocaine, heroin, aspirin, procaline and meperidine (Lotti 1983; Joly
1986; Brzezinski 1997; Pindel 1997). It is therefore important to study the catalytic
mechanism responsible for carboxylesterase induced hydrolysis.
Bacterial lipolytic enzymes have been classified into eight families based on their
sequence identities and enzyme properties (Arpigny 1999). Family VII consists of rather
large number of bacterial esterases with a molecular weight of 55 kDa that share about
30-40% sequence identity. This group of enzymes is widely utilized in several industrial
applications. For example, B. subtilis carboxylesterase was found to efficiently hydrolyze
p-nitrobenzyl esters, which makes it valuable in the final removal of the p-nitrobenzyl
group used as a protecting group in synthesis of the β-lactam antibiotic.

Interestingly,

this group of enzymes is also homologous to mammalian carboxylesterases that are
involved in hydrolysis and detoxification of numerous peptides and drugs and in prodrug
activation. Therefore, enzymes in this family can be used as models to study the reaction
mechanism of the related mammalian carboxylesterases.
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The esterase gene est55 was recently isolated from the genomic library of the
Gram-positive bacterium Geobacillus stearothermophilus and cloned and expressed in E.
coli (Ewis 2004). The est55 gene encodes 498 amino acids with a calculated molecular
mass of 54867 Da. Est55 is active as a monomer with optimal activity for short chain
acyl derivatives of length C4-C6 at a temperature of 60 °C. Est55 belongs to microbial
family VII and shares homology with mammalian carboxylesterases. Est55 shares 32 %
sequence identity with human liver carboxylesterase 1 (hCE1) and 31 % rabbit liver
carboxylesterase (rCE). We hypothesized that Est55 could be used as a model system to
study the catalytic mechanism responsible for mammalian carboxylesterase induced
hydrolysis. In this chapter, the crystal structure of Est55 was determined and mutational
analysis was used to explore the role of C408 in the Est55 enzymatic activity toward pnitrophenyl substrates. This work will help to design a new generation of prodrugs and
pharmaceuticals or to select a new carboxylesterase for prodrug activation or
detoxification of compounds.
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II. MATERIALS and METHODS

Site-directed mutagenesis
Random mutations of C408 were generated by the Quick-Change mutagenesis kit
(Stratagene)

using

the

following

degenerate

primers:

CYS408_f

(5’-

GCTGAAAGCANNNCACGCGCTCGAGCTGCCGTTTGTG-3’) and CYS408_r (5’CGAGCGCGTGNNNTGCTTTCAGCTGGCCGCCGAACAC-3’). 20 ng of plasmid
encoding the est55 gene were mixed with two degenerate primers and 2.5U of pfuTurbo
DNA polymerase, followed by 20 cycles of denaturing, annealing and extension using a
thermal cycler. The reaction mixture was digested by 10 U of Dpn I enzyme at 37 °C for
1h and then transformed into the expression host E. coli Top 10 cells. The mutations were
confirmed by DNA sequencing.

Expression and purification of recombinant Est55
Est55 and the Cys408 mutants were expressed and purified to homogeneity as
described previously (Ewis 2004). Briefly, the enzyme was expressed using E. coli Top
10 cells carrying the recombinant clone pHE55. The wild type Est55 and the mutants
were purified in two steps, ionic exchange using high-load Q-Sepharose HR 26/10
(Pharmacia) and gel filtration using Sephacryl S200 (HR26/60).
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Carboxylesterase assay
The esterase activity of the wild type and the mutant enzymes was measured as
described with modification (Ewis 2004). p-nitrophenyl butyrate was used as the
substrate. The reaction mixture (2 ml) contained 10 mM Tris HCl (pH 8.5) and 0.5 mM
substrate. The amount of p-nitrophenol liberated during the reaction was monitored
continuously at 405 nm in a Carey 3E spectrophotometer (Varian) with a temperature
control module. One unit of activity was defined as the amount of enzyme that releases 1
µmol of p-nitrophenol/min at 37 °C. The molar extinction coefficient of p-nitrophenol is
18,380 M−1 cm−1 at 405 nm. The protein concentration was measured by the Bradford
method (Bradford 1976) with bovine serum albumin as the standard.

Crystallization
Purified Est55 was dialyzed into Tris-HCl buffer at pH 8.0 and concentrated to 710 mg/ml. Est55 was crystallized by hanging drop vapor diffusion at 24 °C using 1 µl of
protein and 1 µl of mother liquor. Crystallization trials used the Hampton PEG/ION
screen. Crystals grew after 7-15 days with 20 % w/v Polyethylene Glycol 3350, 0.2 M
Ammonium Iodide pH 6.2, or 0.2 M Potassium Iodide pH 6.8.

X-ray data collection
Crystals were mounted on a nylon loop and cryo-protected in 20 % (v/v) PEG400
before flash cooling in liquid nitrogen. X-ray diffraction data were collected on a MAR
CCD 225 detector at the SER-CAT beamline of the Advanced Photon Source (APS) at
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the Argonne National Laboratory. The crystal-to-detector distance was 142 mm. The
oscillation angle was 0.25° and the rotation range was 180° for the complete dataset. Xray diffraction data for the crystals grown at pH 6.8 and pH 6.2 were measured to 1.58 Å
and 2.02 Å resolution, respectively.

Structure determination
The X-ray data were integrated using the HKL2000 program (Otwinowski 1997).
The structure of Est55 at pH 6.8 (Est-pH6.8) was determined by molecular replacement
with the CNS package (Brunger 1998).

The structure of Pnb esterase (1QE3) from

Bacillus subtilis was used as a search model (40 % sequence identity) (Spiller 1999).
Data between 15 and 4 Å were used in the rotation research, resulting in one peak. The
rotation solution was then applied in a translation search, yielding a distinct solution with
a correction coefficient of 0.20. After rigid body refinement (CNS) and density
modification using the phase probability distribution calculated from the model and the
experimental amplitudes and solvent flipping, the figures-of-merit improved to 0.82. The
Est55-pH6.2 structure was determined by molecular replacement with the Est55-pH6.8
structure using the program MolRep (Vagin 1997) in CCP4i (Potterton 2003).

Model refinement
Crystallographic refinement of the Est55-pH6.8 structure was initially carried out
using the CNS package (Brunger 1998). The manual building of missing residues of
structure was performed using the graphics program O (Jones 1991). After iteratively
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subjecting the model to several rounds of stimulated annealing and B-group refinement
with CNS and manual rebuilding, the Rfactor and Rfree dropped to 26.4 % and 28.5 %,
respectively. After manual building of the missing residues, SHELX 97 (Sheldrick 1997)
was used to refine the Est55-pH6.8 structure with solvent and isotropic temperature
factors. Crystallographic refinement of the Est55-pH6.2 structure was carried out using
CNS. The final Rfactor and Rfree were 20.0 % and 23.0 %, respectively.

Structural analysis
The Est55 crystal structures at different pHs were superimposed on all Cα atoms
using an implementation of the algorithm described in [Ferro & Hermans, (1977)] (Ferro
1977). The structures of Est55 and the rabbit carboxylesterase were superimposed on all
Cα atoms using the program ALIGN (Cohen 1997). Figures were generated with
MolScript (Kraulis 1991), BobScript (Esnouf 1999) and Raster3D (Merritt 1997).
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III. RESULTS AND DISCUSSION

Crystal structures of Est55
Est55 was crystallized under two different conditions in the presence of the
iodine ion. An example is shown in Figure 3.1. Crystals with similar morphology were
obtained from conditions with different pHs. Est55 was crystallized in 20% PEG3350,
0.2 M Ammonium Iodine (pH 6.2), or 20% PEG3350, 0.2 M Potassium Iodine (pH 6.8).
The higher the pH, the longer the crystals took to grow. The crystallographic statistics
for data collection and refinement are shown in Table 3.1. Both of the Est55 crystal
structures were observed in the space group P212121 with one molecule per asymmetric
unit. The structures were solved by molecular replacement using Pnb esterase (1QE3) as
a search model(Spiller 1999). The pH 6.2 structure (Est55-pH6.2) was refined to an Rfactor of 20.0 % at 2.02 Å resolution. The pH 6.8 structure (Est55-pH6.8) was refined to
R-factor of 17.2 % at 1.58 Å resolution. The higher resolution structure of Est55-pH6.8
had more disorder than the lower resolution structure of Est55-pH6.2. 479 and 463
residues of 498 amino acids of the Est55 structure were positioned in the pH 6.2 and pH
6.8 structures, respectively. Two residues at both termini were not visible in the electron
density maps. Residues were not visible in one or two surface loops and before His409 of
the catalytic triad. Residues 66-76 in a surface loop and 401-404 near the catalytic His
were not visible in Est55-pH6.2. In Est55-pH6.8 the disordered residues were located in
the two surface loops of residue 66-79, 349-358 and 401-407. Cys408 is oxidized with
three oxygen atoms in Est55-pH6.2 ( The detail will be described later).
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Figure 3.1 Crystals of Est55 grown after a few days using hanging drop vapor
diffusion method.
.
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Table 3.1 Crystallographic data collection and refinement statistics for the Est55
crystal structures.
Est55-pH6.2

Est55-pH6.8

Space group

P212121

P212121

Unit cell Å

a=69.529, b=73.485,
c=99.034
67530

a = 69.361 Å, b =
74.430 Å, c = 98.606 Å

0.07 (0.5)

0.08 (0.4)

5.3

5.1

99.1 (95.6)

97.8 (91.5)

17.6

17.5

Resolution Å

10-2.02

10-1.58

Rfactor /Rfree %

20.0/23.0

17.2/23.7

No. residues

479

463

No. water molecules

151

159

3

1

0.006

0.018

1.3a

0.028b

Most favored regions (%)

89.3

89.4

Additional allowed

10.2

10.1

Main chain atoms

35.4

27.9

Side chain atoms

39.4

33.5

Solvent atoms

36.1

39.4

Data collection

Unique reflections
Rmerge (last shell)
Redundancy
Completeness (last shell) %
<I/σ>

71770

Refinement

No. Iodine atoms
rms deviation from ideality
Bond length (Å)
Bond angles
Ramachandran plot

Averaged B-values (Å2)

a

degree

b

angle distances
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Est55 is folded into three domains, a catalytic domain, an α/β domain and a
regulatory domain (Figure 3.2). The catalytic domain shows the typical α/β hydrolase
fold, with a central antiparallel β sheet surrounded by α helices. The two structures of
Est55-pH6.2 and Est55-pH6.8 superimposed with a RMSD value of 0.2 Å for Cα atoms,
which indicated that there were no significant conformation changes in the overall
structure. The Est55 structure was similar to that of rabbit carboxylesterase (rCE)
(Bencharit 2003) (PDB entry 1K4Y) with an RMSD of 1.32 Å over 379 Cα atoms,
although the regulatory domains showed significant differences (Figure 3.3).

Iodine in the Est55 structure
Iodine was present during crystallization. Three iodine atoms were identified in
the Est55-pH6.2 structure, and one iodine in the Est55-pH6.8 structure (Figure 3.4). One
iodine binding site was conserved in both structures with 0.65 occupancy in the Est55pH6.2 structure and 0.34 occupancy in the Est55-pH6.8 structure, respectively. The
iodine atom was identified by the very high level of electron density, even in the 2Fo-Fc
map contoured at 10σ level, as shown in Fig 4a. The iodine had a potential hydrogen
bond interaction with the amide of Asp309 and van der Waals interactions with the
hydrophobic side chains of Phe488, Val372, and Thr367 and Arg393. Two other iodines
were observed in the Est55-pH6.2 structure. One iodine atom with 0.65 occupancy was
located near the active site and had hydrogen bond interactions with amides of Ala407
and Cys408, the carbonyl oxygen of Cys408 and two water molecules. It formed van der
Waals interactions with the side chains of Phe112, Lys406, Cys408 and the main chain of
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Active Site
Catalytic
domain

α/β domain

Regulatory
domain

Figure 3.2 Overall structure of carboxylesterase Est55 comprising three domains.
The catalytic domain is in magenta, the α/β domain is in blue and the regulatory domain
is in yellow. The catalytic residues Ser194, Glu310, and His409 are shown in green ball
and stick representation. Black arrows point to two missing loops in the Est55-pH6.2
structure, which are indicated by the dashed lines.
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Figure 3.3 Superposition of Est55 and rabbit carboxylesterase (1K4Y) structures.
Est55 is colored green and 1K4Y is colored red. The black arrow indicates the regulatory
domain, which shows significant difference in the two structures.
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Figure 3.4 Iodine in the crystal structure. 2Fo-Fc electron density map contoured at
2.0σ. Interatomic interactions are shown as dashed lines with distances in Å. A)
conserved iodine site and B) second site in Est55-pH6.2. Cys408 is oxidized with three
oxygen atoms.
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Gly108 (Fig 3.4b). The third iodine was refined with partial occupancy and was located
on the surface of the protein with an ionic interaction with the side chain of Arg377, a
hydrogen bond interaction with amide of Ala400, and van der Waals interactions with
main chain atoms of Pro399 and side chain of Glu290. This iodine was located right next
to the disordered loop 401-404 in the active site. It was positioned partly in the density
for one alternate conformation of the side chain of Arg293, indicating that the Arg293
side chain is in the other conformation in the presence of iodine ion. The hydrogen bond
interactions observed between three iodine atoms and the amides of the protein are NH….I interactions, with N….I distances in the range of 3.3-3.9 Å. Similar hydrogen bond
distances were observed in the small molecule crystal structures (Sheldrick 1970; Dale
2005).

Flexibility of the active site
The electron density in the active site region showed partial disorder in Est55pH6.8, while the residues were clearly visible in Est55-pH6.2. In the Est55-pH6.8
structure, the loop containing the catalytic His409 was partially disordered and residues
401-407 were not visible. Only one water molecule was visible and it formed hydrogen
bond interactions with the side chains of Ser220 and two of catalytic triad residues
Ser194 and Glu310. However, the structure of Est55-pH6.2 showed more ordered density
near the active site. The loop around His409 showed clear electron density and residues
405-409 were fit into the electron density unambiguously. The conformation of this loop
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was stabilized by several hydrogen bond and van der Waals interactions with the
surrounding residues in the active site (Figure 3.5).
The catalytic triad of Est55 consists of Ser194, Glu310, and His409. The
catalytic Ser194 was located at the bottom of a deep active site cleft and formed watermediated hydrogen bond interactions with the carboxylate side chain of Glu310 (Fig 3.5).
Although, the side chain of His409 was positioned unambiguously in Est55-pH6.2 and
Est55-pH6.8 structure, it was directed away from the other members of the catalytic triad,
Ser194 and Glu310, and did not show the hydrogen bond interactions with their side
chains that are expected for the catalytic triad. Moreover, His409 was located near a
disordered loop in both Est55 structures. These observations suggested that the flexibility
of the loop where His409 is located plays an important role in substrate binding and
catalysis. It is likely that the active site is not formed until the substrate is bound within
the catalytic gorge. The rCE structure also showed flexibility near the catalytic site.
Disorder was observed for two loops in the rCE structure adjacent to the catalytic triad
residues Glu353 and His467. Also, the catalytic Glu353 was rotated away from the active
site relative to the conserved orientations observed in other esterases. Therefore, the
existence of disordered active sites suggests that Est55 and rCE enzymes will bind
substrate by an induced fit mechanism.

Est55 contains an oxidized cysteine in the active site.
Extra electron density was observed near the side chain of Cys408 in Est55-6.2
structure (Figure 3.6a). This density indicated the presence of three oxygen atoms within
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Ala195
Ser220 2.8
2.7

Glu310

Ser194

2.9

2.8

3.1

2.7

2.9
2.8

2.5
3.0

2.3

2.8

Cys408

3.0
3.3
2.5

2.8
3.2

Gly108

2.8

Ala109

His409

Ala407

Figure 3.5 The active site region of Est55. Interatomic interactions are shown in dashed
lines with distances in Å. The catalytic residues Ser194, Glu310 and His409 are labeled
in red.
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A

B

C

Figure 3.6 Oxidized cysteine. A) 2Fo-Fc electron density map contoured at 1.6 σ and Fo-Fc electron density map
contoured at 3.5 σ before three oxygen atoms were positioned. B) 2Fo-Fc electron density map contoured at 1.6 σ after
addition and refinement of two oxygen atoms and C) three oxygen atoms.
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bonded distance of the cysteine sulfur. Refinement confirmed that the cysteine was
oxidized to the sulfinylperoxy form of SO2O- (Figure 3.6c). This oxidation state is
unusual, however, similar forms have been observed in oxidized small molecules at low
temperatures. The small molecule sulfinylperoxy intermediate (-SO2O-) and cysteine
sulfonyl peroxyl radicals (-SO2- and SO2OO-) have been reported (Kim 1988; Sevilla
1990). In Est55 the oxidized cysteine was stabilized by hydrogen bond interactions with
amides of Gly108, Ala109 and Ala195 and two water molecules in the oxyanion hole, as
shown in Figure 3.5. Unexpectedly, Cys408 occupied the oxyanion hole of the active site
and blocked the entrance of the active site cavity, and appeared to mimic an inhibitor.
Five water molecules occupied the active site and made hydrogen bond interactions with
the side chains of Ser194, Ser220, Glu310, Cys408 and the amide of His409.
The presence of oxidized cysteine has been described in several protein structures,
mainly in the form of cysteine sulfenic acids (Cys-SOHs), sulfinic acids (Cys-SO2 H) and
sulfonic acids (Cys-SO3H). Some of these oxidized cysteines have been reported to play
roles in enzyme catalysis (Stehle 1993; Mande 1995; Mizohata 2005). In

NADH

peroxidase, a conserved cysteine functions as a redox center that cycles between
sulfhydryl (Cys-SH) and sulfenic acid (Cys-SOH) states (Stehle 1993; Mande 1995). In
peroxiredoxins, a conserved redox-active cysteine is oxidized to a cysteine sulfenic acid
after attacking the peroxide substrate (Mizohata 2005). Oxidized cysteines with no
apparent roles in catalysis have also been reported in some enzymes. Cysteine sulfinic
acid has been described in the crystal structure of α-glucosidase AglA with a possible
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role in enzyme inactivation. The oxidized cysteine prevents the catalytic histidine from
interacting with an Mn2+ ion and the potential nucleophile Asp (Lodge 2003).
Several studies have indicated a correlation between the cysteine oxidation and
the oxidative stress response (Canet-Aviles 2004). Cysteine-sulfinic acid resulting from
cysteine oxidation of human Parkinson's disease protein DJ-1 can signal mitochondrial
relocalization and protect against cell death in response to the oxidative stress (CanetAviles 2004; Kim 2005; Moore 2005). The cysteine oxidization was also observed in a
prokaryotic homologue of DJ-1, the YajL protein from Eschericha coli (Wilson 2005).
Furthermore, the NADH peroxidase and peroxiredoxin, which contain oxidized cysteines,
are involved in the defense mechanism against oxidative stress. Interestingly, it has been
observed that Est55 is secreted during the stationary phase (unpublished observation).
During this stage of cell growth, bacteria are exposed to several environmental stresses,
one of which is oxidative stress. Based on the crystal structure of Est55-pH 6.2, it is
tempting to suggest that cysteine oxidation of Est55 may provide a possible cellular
mechanism in response to oxidative stress during the stationary phase. The activity of
Est55 would be inhibited by the oxidization of Cys408.

Role of Cys408 in the enzymatic activity of Est55
In order to investigate the role of C408 in the reaction mechanism of Est55, a
random mutant library of C408 was constructed using the Quick-change site-directed
mutagenesis kit with degenerate primers. Mutations to the hydrophobic amino acids
C408A, C408P, C408V, the polar amino acid C408S, and the flexible amino acid C408G
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were selected to test the enzymatic roles of cysteine. The different mutants were
identified by DNA sequencing. All mutants were purified to homogeneity and their
enzymatic activities were compared with that of the wild type enzyme. The enzymatic
activity for p-nitrophenyl substrate (p-nitrophenyl butyrate, p-NP butyrate) was measured
for both the wild type and the mutants to evaluate the effect of the mutants on catalysis.
The kinetic parameters are shown in Table 3.2. Little variation was observed in the Km
for the wild type Est55 and the mutants, except for C408S. Mutations to hydrophobic
amino acids, C408A, C408P, and C408V, showed similar Km values as the wild type.
However, mutation to polar serine in C408S resulted in 4-fold increased Km value,
suggesting that a polar environment is less favorable for substrate binding. Substitutions
of Cys408 showed conserved or improved kcat value, except for C408G that showed a 4
fold decrease in kcat relative to wild type Est55. Overall, the C408S and C408G mutants
demonstrated decreased catalytic efficiency for p-NP butyrate hydrolysis. The lower
activity of the serine mutant is consistent with the hydrophobic nature of the Est55
substrate binding pocket. This pocket is formed by the hydrophobic side chains of
Phe112, Trp119, Leu225, Leu226, Met274, Leu313, Phe314, Leu316, Val370, Phe371,
and Leu411. Moreover, the lower activity of C408G suggested that the very flexible
amino acid glycine was unfavorable at this position. Overall, the analysis of these
mutations suggested that cysteine408 is not essential for activity, and the substitution of
hydrophobic side chains of alanine or valine in fact produces higher enzyme activity.
However, these results do not rule out a possible role of C408 in the regulation of Est55
activity in vivo.
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Table 3.2 Effects of mutation at Cys408 on the hydrolysis of p-NP butyrate.
Km (µM)

kcat ( s-1)

kcat/Km ( s-1 µM-1)

WT

24.2 ± 2.5

(7.9 ± 0.3) x 105

(3.3 ± 0.4) x 104

C408A

32.8 ± 2.9

(13.7 ± 0.4) x105

(4.2 ± 0.4) x 104

C408G

23.1 ± 2.7

(2.2 ± 0.09) x 105

(0.95 ± 0.17) x104

C408P

26.0 ± 3.2

(6.5 ± 0.3) x 105

(2.5 ± 0.3) x104

C408S

97.5 ± 4.3

(12.7 ± 0.6) x 105

(1.1 ± 0.05) x 104

C408V

28.3 ± 3.8

(10.7 ± 0.3) x 105

(4.5 ± 0.6) x104
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CHAPTER 4

The Potential for Use of Bacterial Carboxylesterase Est30 and Est55 in Cancer Gene
Therapy
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I. INTRODUCTION
Carboxylesterases were introduced in cancer therapy for activating the prodrug
irinotecan (7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin; CPT11) in 1998 (Kojima 1998). CPT-11 is a prodrug that can be activated by a
carboxylesterase to generate SN-38 (7-ethyl-10-hydroxycamptothecin), a topoisomerase I
poison. CPT-11 is a water-soluble derivative of camptothecin, an alkaloid originally
extracted from the Chinese tree Camptotheca acuminata. CPT-11 has shown significant
anti-tumor activity in human tumor xenograft models, especially for colon cancer
(Taguchi 1990). Although SN-38 can be detected in the plasma of patients within minutes
after administration of CPT-11 (Gupta 1997), only a small percentage of CPT-11 was
converted into SN-38 (Rivory 1997). Therefore, several cDNAs encoding different
carboxylesterases, including rabbit liver carboxylesterase (rCE), human small intestine
(hiCE) and human liver carboxylesterase 2 (hCE2) have been isolated and their
enzymatic roles for CPT-11 activation were explored (Potter 1998; Humerickhouse 2000;
Khanna 2000). To date, rabbit carboxylesterase (rCE) is considered the most efficient
enzyme, which activates CPT-11 within 22 hours under the conditions of applying 2000
units of the enzyme (Danks 1999).
The application of mammalian enzymes has the advantage of lower
immunogenicity, which supports longer periods of prodrug activation (Aghi 2000).
However, they lack the advantage of the large therapeutic index and high thermostability
that can be achieved with enzymes from thermostable bacterial origins. The esterase
genes est55 and est30 were recently isolated from the genomic library of the Gram-
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positive bacterium Geobacillus stearothermophilus and cloned and expressed in E. coli
(Ewis 2004). They showed high thermostability and remained active at mesophilic
temperature. Est55 shares 32 % sequence identity with human liver carboxylesterase 1
(hCE1) and 31 % rabbit liver carboxylesterase (rCE). It also showed higher enzymatic
activity than rCE towards the same p-nitrophenyl esters (Ewis 2004), which have a
similar molecular diameter to CPT-11. Therefore, we hypothesized that Est55 can
activate CPT-11. Although there is no sequence homology between Est30 and Est55,
they share similar substrate specificity (Ewis 2004), which suggests the possibility that
Est30 also may activate CPT-11. In this chapter, we measured the ability of these two
enzymes to activate CPT-11 and compared their catalytic efficiency. We also analyzed
the role of Cys408 in the Est55 enzymatic activity towards CPT-11. Finally the effects of
Cys408 mutants were compared for hydrolysis of p-NP butyrate and CPT-11.
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II. MATERIALS and METHODS

Site-directed mutagenesis of Est55
Random mutations of C408 were generated by the Quick-Change mutagenesis kit
(Stratagene)

using

the

following

degenerate

primers:

CYS408_f

(5’-

GCTGAAAGCANNNCACGCGCTCGAGCTGCCGTTTGTG-3’) and CYS408_r (5’CGAGCGCGTGNNNTGCTTTCAGCTGGCCGCCGAACAC-3’). 20 ng of plasmid
encoding the est55 gene were mixed with two degenerate primers and 2.5 U of pfuTurbo
DNA polymerase, followed by 20 cycles of denaturing, annealing and extension in a
thermal cycler. The reaction mixture was digested by 10 U of Dpn I enzyme at 37 °C for
1h and then transformed into the expression host E. coli Top 10 cells. The mutation sites
were confirmed by DNA sequencing.

Expression and Purification of Recombinant Est55
Est55 and Cys408 mutants were expressed and purified to homogeneity as
described previously (Ewis 2004). Briefly, the enzyme was expressed using E. coli Top
10 cells carrying the recombinant clone pHE55. The wild type Est55 and the mutants
were purified in two steps, ionic exchange using high-load Q-Sepharose HR 26/10
(Pharmacia) and gel filtration using Sephacryl S200 (HR26/60).
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Expression and Purification of Recombinant Est30
The coding sequence of est30 amplified by PCR was cloned into the pBAD-HisA
vector (Invitrogen) and the resulting recombinant plasmid was designated pHE30.
Escherichia coli Top10 (Invitrogen) harboring pHE30 was induced for 4 h by 1 mM
arabinose in 1 liter culture and then harvested at 5000 g for 15 min at 277 K. The cell
pellet was suspended in 40 ml of hypertonic solution consisting of 20 mM Tris-HCl pH
7.5, 2.5 mM EDTA and 20% sucrose. The suspension was incubated on ice for 30 min
and vortexed every 10 min. Cells were removed by centrifugation at 13 000g for
20 min at 277 K and the cell pellet was resuspended in 60 ml of 20 mM Tris-HCl pH
7.5, 2.5 mM EDTA (hypotonic solution) and further incubated on ice for 30 min with
intermittent vortexing every 10 min. Cells were removed by high-speed centrifugation at
22 000g for 20 min at 277 K and the supernatant applied to a Pharmacia Q-Sepharose
Hiload 26/10 HP that was equilibrated with 50 mM Tris-HCl pH 8.0. The column was
washed with 150 ml of the equilibration buffer to remove unbound proteins, followed by
a linear gradient to 50 mM Tris-HCl pH 8.0 and 1 M KCl. The esterase peak eluted at
0.65 M KCl. Fractions containing esterase activity were pooled (32 ml), concentrated to
5 ml by ultrafiltration and applied to a Sephacryl S 200 HR column (Pharmacia, 26/60).
The enzyme was eluted using 50 mM potassium phosphate pH 7.0 and 0.15 M NaCl.

HPLC Assay for Enzymatic Conversion of CPT-11 to SN-38
The enzymatic reaction was carried out as described before with minor
modifications (Guichard 1998). In brief, freshly purified Est55 and Est30 were incubated
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with different concentrations of CPT-11 from 1.67 µM to 100 µM in a final volume of
300 µl of 50 mM HEPES (pH 7.4) at 37 °C for 8hrs. The reaction was terminated with
the addition of one volume of 75mM Ammonium acetate (pH 4.0), vortexed, and
centrifuged at 14,000 g for 2 min. The kinetic parameters for conversion of CPT-11 were
obtained from HPLC separation of substrate and product.
HPLC analysis for CPT-11 and SN-38 was performed as described (Danks 1999).
An aliquot of the reaction was injected onto an AnlantisTM dC 18 chromatography column
(4.6 x 50 mm) using an automatic injector (Amersham A-900) and was run by HPLC on
an AKTA Purifier. A linear gradient was run with 75mM ammonium acetate (pH 4.0),
and 0 to 25% acetonitrile to separate the substrate and product. The reaction mixture was
eluted at 1ml/min. Under these conditions, the CPT-11 and SN-38 were eluted at 3.8 ml
and 5.1 ml, respectively. The two compounds were detected by UV absorbance at
wavelengths of 266 nm and 375 nm, respectively. The absorbance was converted to SN38 concentration via the standard calibration curve of UV peak area generated by known
concentrations of SN-38. Kinetic parameters were determined by fitting the data obtained
at less than 20 % substrate hydrolysis for the Michaelis-Menton equation using the
SigmaPlot 8.0.2 program (SPSS, Inc.).
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RESULTS AND DISCUSSION

Both Est30 and Est55 can convert CPT-11 to SN-38
Freshly purified Est30 and Est55 were used to measure their ability to convert
CPT-11 to SN-38. The enzymatic conversion of CPT-11 to SN-38 was quantitated by
HPLC separation of the substrate and product. The peak positions for CPT-11 and SN-38
were confirmed by using the pure compounds. Also, the presence of SN-38 was
confirmed by mass spectrometry of the isolated fraction giving the molecular mass of
393.1. Est55 activated CPT-11 with a kcat/Km value of 0.84 ± 0.08 min-1 mM-1 (Table 1).
Est30 activated CPT-11 with a kcat/Km value of 0.09 ± 0.01 min-1 mM-1. In comparison
with the published kinetic data for other carboxylesterases, these two enzymes showed
lower catalytic efficiency than rabbit carboxylesterase (180 min-1 mM-1) (Wierdl 2004).
However, Est55 and Est30 have the advantages of high thermostability and catalytic
efficiency at mesophilic temperature. Proteins of bacterial origin are relatively easy to
overexpress, purify and engineer, which is an advantage for the long term goal of
selecting efficient stable enzymes for CPT-11 activation. Therefore, Est55 and Est30 can
provide enzymes with high stability for efficient cancer therapy with CPT-11.
The kinetic constants were used to compare the differences between Est55 and
Est30 in catalytic efficiency towards CPT-11 (Table 4.1). A Lineweaver–Burk plot
showed a linear response over the tested concentration range. The Km and kcat values of
Est55 were estimated to be 18.6 ± 1.8 µM and (15.6 ± 0.5) ×10-3 min-1, while those of
Est30 were 202 ± 20 µM and (17.2 ± 1.2)×10-3 min-1. These results indicate that Est30
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Table 4.1 Kinetic parameters for Est55 and Est30 with CPT-11.
Km (µM)

kcat ( min-1)

kcat/Km ( min-1 mM-1)

Est55

18.6 ± 1.8

(15.6 ± 0.5) × 10-3

0.8 ± 0.08

Est30

202 ± 20

(17.2 ± 1.2) × 10-3

0.09 ± 0.01
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has much lower substrate binding affinity than Est55, and consequently the catalytic
efficiency (kcat/Km) of Est30 (0.09 ± 0.01 min-1 mM -1) is about 10-fold lower than that of
Est55 (0.8 ±0.08 min-1 mM -1 ).

Effects of mutation of Est55 at Cys408 on the hydrolysis of CPT-11
The Cys408 mutants of Est55 were evaluated for hydrolysis of CPT-11 to SN38 (Table 4.2). Various effects on prodrug activation were observed for the different
substitutions of Cys408. The most dramatic effect was observed for the C408S mutant,
where no product peak for SN-38 was detected even after doubling the incubation time.
Therefore, mutation to the polar serine has eliminated the ability to hydrolyze CPT-11.
Mutation to glycine resulted in ~four-fold decrease in kcat/Km.

Substitution of

hydrophobic amino acids had variable effects on kinetic parameters. The C408A mutant
showed more than 2-fold increase in Km, while C408P and C408V had ~3- to 5-fold
decreased kcat relative to wild type Est55. The two mutants C408A and C408P had
decreased catalytic efficiency of 40 and 17 % of wild type kcat/Km,, respectively. The
C408V mutant showed the highest catalytic efficiency of 70 % relative to the wild type
Est55.
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Table 4.2 Effects of mutation at Cys408 on the hydrolysis of CPT-11.
Km (µM)

kcat ( min-1)

kcat/Km ( min-1 mM-1)

WT

18.6 ± 1.8

(15.6 ± 0.5) ×10-3

0.8 ± 0.08

C408A

45.3 ± 6.9

(15.5 ± 0.35) ×10-3

0.34 ± 0.05

C408G

22.4 ± 1.4

(5.0 ± 0.12) ×10-3

0.23 ± 0.02

C408P

20.6 ± 2.1

(2.9 ± 0.1) ×10-3

0.14 ± 0.01

C408S

N. D.*

N. D.*

N. D.*

C408V

22.3 ± 2.5

(13.5 ± 0.6) ×10-3

0.6 ± 0.07

* Not detectable
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The effects of the Cys408 substitutions on Est55 activity differed for the two tested
substrates, p-NP butyrate and CPT-11, as shown in Figure 4.1. Hydrolysis of p-NP
butyrate showed relatively little change (76-140% of wild type Est55) for the mutations
to hydrophobic amino acids, alanine, valine and proline, whereas, substitution of glycine
or serine was unfavorable and resulted in only about 30% of wild type catalytic
efficiency. In contrast, hydrolysis of CPT-11 was substantially reduced for all the tested
mutants of Cys408, except C408V. In fact, the serine mutant had no detectable activity.
These results suggested that the hydrophobicity of the binding site was more critical for
binding and hydrolysis of CPT-11 compared with p-NP butyrate. Mutant C408V may
provide a more stable construct by removing the only cysteine residue, which can oxidize
as shown in the crystal structure and potentially inhibit Est55 activity.

Attempts to obtain structures of Est55 with substrates, products and inhibitors
Although Est55 and Est30 did not show higher catalytic efficiency than that of
rCE, their high thermostability and bacterial origins make them promising candidates for
activating CPT-11. However, protein engineering has to be pursued. Directed evolution is
a very common approach for improving enzyme activity even after the three dimensional
structure of enzyme has been determined because the rational design based on the
structure usually focuses on the enzyme active site only, while sometimes a mutation far
from the active site may have dramatic effects on enzyme activity. Directed evolution has
been successfully used to improve the stability and activity of a carboxylesterase from
Bacillus subtilis, which can selectively cleave the p-nitrobenzyl ester of Loracarbef, a
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Figure 4.1 Relative activity of Est55 Mutants on p-NP butyrate and CPT-11
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cephalosporin. The wild type enzyme has very weak activity in the presence of
dimethylformamide (DMF), which is used for dissolving the substrate. The combination
of DNA shuffling and error-prone PCR generated a mutant with 150 times higher activity
compared to the wild type enzyme. Error-prone PCR by the addition of manganese
chloride was performed on est55 gene. A high throughout screening method using a
substrate mimicking the size of CPT-11 is under development. Those variants with higher
enzymatic activity towards that substrate will be further tested for the activation of CPT11 by the HPLC assay.
In addition to creating genetic diversity from a pool of variants from a single
gene, a recent approach called family shuffling allows two or more naturally occurring
homologous genes to be used as the starting genetic material. In family shuffling, the
homologous genes are mixed, randomly fragmented and recombined under the conditions
that permit annealing and extension of nonidentical complementary strands. Such related
genes, which have been selected from nature to be functional and useful, provide
functional diversity as opposed to simply random mutants (Svendsen 2004). The power
of this method has been demonstrated in the directed evolution of thymidine kinase for
AZT phosphorylation using DNA family shuffling (Christians 1999). Since several
carboxylesterases have shown the ability to activate CPT-11, family shuffling of this
pools of genes is another possible approach to select a more active mutant (Potter 1998;
Danks 1999; Danks 2004).
Rational design based on the crystal structure of Est55 to improve its enzymatic
activity can be also attempted. Unfortunately, the Est55 structure is in an inactive form,
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with the catalytic His409 rotated away from the other two members of the catalytic triad,
Ser194 and Glu310.

The presence of the inactive form maybe due to the pH of

crystallization conditions in the range of pH 6 to pH 7. At these pH conditions, the
enzyme maintains only slight activity (Ewis 2004). In order to get a structure in an active
form, crystallization at the basic pH in which this protein is more active was tested,
however crystals were either in the needle shape or too small and no useful data have
been obtained. As a structure of an enzyme in complex with either a substrate or a
product may provide more detailed information about the enzyme reaction mechanism,
which is critical for designing a mutant with higher enzymatic activity, several
experiments have been performed to achieve this goal (Table 4.3). In order to obtain an
enzyme-substrate complex structure, the catalytic triad Ser194, Glu310, and His409 were
mutated to Alanine individually to eliminate the enzyme activity. All these mutant
enzymes were expressed, purified, and cocrystallized with the substrate CPT-11.
Glu310Ala-CPT11 crystals appeared after a few days, however, the crystals were not big
enough to diffract. Also, co-crystallization of the wild type protein or soaking wild type
Est55 crystals with the two products SN-38 and 4PP was tried. No electron density was
observed for the products in all the data sets collected, even though the products and the
enzyme are in high molar ratio, for example the molar ratio of Est55 and 4PP is 1:1000.
Since there was no success in obtaining the enzyme-substrate or enzyme-product
complex by either co-crystallization or soaking, and the inactive form of the enzyme
structure makes it difficult to model the ligands into the active site, an alternative
approach has to be tried. Crystallization of Est55 with inhibitors was attempted.
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Table 3 Crystallization trials of Est55 wild type and mutants with different ligands.
Ligand

Results

Est55

CPT-11

Crystals diffract,
No density for substrate

Est55

SN-38

Crystals diffract,
No density for product

Est55

4PP

Crystals diffract,
No density for product

Ser194Ala

CPT-11

No crystals

Glu310Ala

CPT-11

Crystals are too small

His409Ala

CPT-11

No crystals

Est55

Phenylmethylsulphonylfluoride No crystals
(PMSF)

Est55

N-p-Tosyl-L-phenylalanine
chloromethyl ketone (TPCK)

No crystals
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Unfortunately, Est55 could not be fully inhibited by all known commercial serine
protease and carboxylesterase inhibitors. We accidentally found that Est55 can be
inhibited by a protease inhibitor cocktail tablet. Although the specific inhibitors have not
been identified, crystallization of Est55 with the cocktail will be attempted.
Once a structure is available for Est55 in complex with substrate, a product or an
inhibitor, we can elucidate the detailed information of the key residues involved in
substrate binding and product release. Site-directed random mutagenesis of those residues
in the active site can be performed in the next step. Those improved clones from either
directed evolution or rational design will be combined, re-mutated, and screened for
higher catalytic efficiency.
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